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Abstract 
 
In this study, which was conducted between March 2007 and December 2008, the crystal 
structure of the alpha polymorph of phenylbutazone has been determined by single crystal X-
ray diffractometry. The present findings support those of Singh & Vijayan (1977) and 
Paradies (1987). Efforts to grow single crystals of the beta and delta polymorphs of 
phenylbutazone did not locate specimens of adequate quality for structure determination. 
Nonetheless it was possible to isolate high purity powder samples of these two forms. The 
powder diffraction pattern of the delta polymorph was measured with improved accuracy at 
the Diamond synchrotron, and reveals a number of peak overlaps in previously published 
diffraction patterns of this crystal form. The improved diffraction data have enabled the 
crystal system of the delta form to be identified as orthorhombic, and space-group selection 
has been narrowed down to Pnn2 or Pnnm. 
Four new solvated forms of phenylbutazone have been identified. The crystal structures of 
two of these new solvates have been determined by single crystal diffractometry. Both have 
space-group C2/c, and may be considered isostructural with five formerly identified solvates, 
whose structures were published by Hosokawa et al. in 2004.  
Previously phenylbutazone has been found to change polymorphic forms at above-ambient 
temperatures. This behaviour has been examined both in a differential scanning calorimeter 
and on a powder X-ray diffractometer equipped with isothermal sample heating, where the 
transition of the alpha and beta polymorphs to the delta polymorph was observed. 
Thermodynamic methods of predicting the transition temperatures of polymorphs are 
discussed, particularly those derived from dissolution data. In the case of phenylbutazone, a 
substantial amount of dissolution data has been collected elsewhere, and these data are used 
to generate computational predictions of the polymorphic transition temperatures for 
comparative purposes. 6 
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1  Molecular Polymorphism 
1.1  Introduction 
 
Scientists and non-scientists alike are instinctively aware of the ability of the substances that 
they encounter to take up a variety of different crystal packing arrangements. This 
phenomenon, which is known as allotropism among elements of the periodic table, is readily 
apparent to the layman familiar with the manifold forms of the element carbon: graphite is 
one allotrope of carbon, while diamond is another. The fact that these two substances, which 
differ only in their packing arrangement, exhibit such strikingly different physical properties, 
underscores the importance of an understanding of crystal structure, and raises the prospect of 
valuable discoveries, where new crystal forms possessing useful properties can be identified 
and isolated. 
In molecular compounds the existence of multiple crystal packing arrangements is termed 
polymorphism. The reader is referred to the extensive literature on the subject for a 
comprehensive set of definitions, [1-3]. In those instances where a stable crystal form 
contains solvent bound-up in a regular arrangement in the crystal lattice, the crystal form is 
designated as a solvate or solvated form. This phenomenon is sometimes referred to as 
pseudo-polymorphism. 
An understanding of the conditions under which a substance changes from one crystal form 
to another is of importance in ensuring that the material is produced and delivered in the 
desired form, and may also have value in the design of manufacturing techniques.  
Although wide divergences in physical properties such as those between graphite and 
diamond are rarely encountered among different polymorphs, less pronounced differences are 
commonplace, resulting primarily from differences in the lattice energies of the individual 13 
crystal structures. These divergences often give rise to differences in the density and 
dissolution rates of individual crystal forms. Despite the potentially adverse consequences for 
formulators resulting from differences in crystal packing arrangements, formal specifications 
for polymorphic form are seldom encountered outside the pharmaceutical industry. 
Study of polymorphism has established roots, and is carried out systematically in certain 
industries. The pharmaceutical industry is required to screen the various polymorphic forms 
of its ingredients, [4, 5], both to maintain uniform processing during manufacture, and to 
ensure predictable dissolution and bioavailability of solid dosage forms in vivo. Nonetheless 
a number of instances have occurred, in which the existence of a new crystal form has 
emerged only during the later stages of product development, [6].  
Many APIs, including phenylbutazone, lack water-solubility, and must therefore be specially 
formulated and/or chemically modified in order to be administered. Among the techniques to 
achieve this objective are, [7];  
  Micronization  
  Preparation of salts of the API 
  Use of surfactants 
  Compounding with water-soluble carriers; e.g. cyclodextrin, liposomes or dendrimers 
Selection of more soluble polymorphic forms may also be helpful. During formulation and 
subsequent manufacturing, the difference in solubility of particular polymorphs needs to be 
taken into account, along with the many other factors that affect solubility; for example, the 
compression force used to manufacture tableted forms of pharmaceutical preparations. 14 
Routine quality control tests, such as powder X-ray diffraction, readily show up changes in 
the polymorphic form of end products and intermediates subsequent to specific 
manufacturing processes, however the determination of the full crystal structure, a proof of 
what underlies the quality control procedure, remains in many cases an elusive goal. 
With a view to simplifying the workflow of drug development groups, in particular, much 
theoretical effort has been expended to develop computational methods capable of predicting 
how individual molecules are likely to pack, solely by using thermodynamic and geometric 
measurements. These models have been put to the test in series of blind tests organized by the 
Cambridge Crystallographic Data Centre. The model developed at UCL by Professor S. 
Price’s group, [8], searches for packing arrangements that are predicted to have low lattice 
energies. Although notable successes have been achieved in predicting stable polymorphs 
computationally, this approach tends to generate a larger number of putative polymorphic 
forms than are actually found to exist, [9, 10].  
Nevertheless prediction techniques such as these have the potential to augment purely 
crystallographic methods of achieving the challenging objective of determining the crystal 
structure of  ever larger molecules purely from their powder X-ray diffraction patterns, [11]. 
 
1.2  Designation of Polymorphs 
 
Several investigators refrain from assigning names to identified crystal forms, referring 
instead to a form number. This less specific designation circumvents the pitfall of assigning a 
transferable nomenclature to a species, whose nature is not necessarily fully apparent; for 
instance a crystal form that is not a polymorph but, in fact, a solvated form. A methodology 
for distinguishing between solvated and non-solvated forms is described in Section 2.1. 
Bernstein points out that no formal rules exist for the labelling of polymorphs; Greek letters, 15 
Roman letters and Roman numerals are the most frequently encountered designations. In this 
investigation Greek letters have been adopted to identify polymorphs of the molecule under 
study, mainly because substantial previous investigation has led to the emergence of a 
reasonably robust nomenclature based upon the Greek alphabet. In the case of solvates, the 
crystal form is identified as a solvate of the target molecule with a particular solvent. This 
does not address the possibility that there may be more than one solvate of a particular 
molecule with the solvent in question, an issue that is discussed further in the context of 
structural identification of phenylbutazone’s solvates. 
 
1.3  Phenylbutazone 










Figure 1 – Phenylbutazone 
 
Phenylbutazone, (1,2-diphenyl-4-n-butyl-3,5-pyrazolidinedione), is an active pharmaceutical 
ingredient, API, which is used primarily in non-steroidal, anti-inflammatory preparations to 
relieve pain associated with arthritis and other chronic musculoskeletal conditions. It also 
possesses antipyretic and analgesic effects, [12, 13].  16 
The first commercial dosage form was launched in 1952 by the Swiss firm, Geigy, under the 
trade-name Butazolidin
®. Bulk synthesis was carried out using malonic acid ester, [14], as 
starting ingredient. In humans the drug has since been found to be toxic to bone marrow, and 
it is therefore no longer administered in several countries. However it still finds application in 
veterinary preparations, particularly in those for horses.  
The compound is known to form solvates, [13, 15], readily in a range of common 
crystallization solvents. Furthermore, phenylbutazone exists in at least three polymorphic 
forms, which can be obtained by conventional, evaporative solvent crystallization [16-19], as 
well as at least one other which has been prepared both by grinding, [20] and spray-drying, 
[21-23].  A further two polymorphs have been reported to exist. Literature findings are 
summarized in the following section; (Table 1). 
Transitions of solid phenylbutazone crystal forms to other forms have been widely reported, 
and there is consensus that the form known as the delta form is the polymorph which is 
formed upon heating of the other polymorphic forms, [18, 24, 25]. Descriptions of the nature 
of these transitions are less consistent. Certain researchers have suggested that melting of the  
polymorph undergoing transition takes place followed by recrystallization in the delta form. 
There are no reports of reversibility of the transitions; once the alpha or beta form sample has 
changed to the delta polymorph, recooling does not result in a retransition from the delta form 
to other polymorphs. 
Upon melting and subsequent refreezing, phenylbutazone is observed to form a wax-like 
mass, which exhibits little or no crystallinity. Conversely phenylbutazone is observed to 
crystallize readily from organic solution, under most conventional crystallization conditions, 
into highly-ordered polymorphic forms with little or no amorphous content. 17 
Although readily soluble in a wide range of organic solvents, phenylbutazone is barely 
soluble in water. Dissolution in aqueous buffer solutions is possible, and the solubility of the 
compound has been comprehensively studied across a range of common processing 
temperatures in phosphate buffer solutions, [17-19, 26-28] . Furthermore phenylbutazone is 
among a relatively small number of pharmaceutically active ingredients whose solubility 
parameter has been studied in detail, [29], enabling its solubility to be predicted in a wide 
range of common solvents according to the methodology developed by Hildebrand, Prausnitz 
and Scott, [30-33]. 
The tendency of phenylbutazone’s polymorphs to display varying rates of dissolution is 
examined in depth by Tuladhar et al., [19, 28, 34], Kaneniwa et al., [26] and Al-Meshal, [35]. 
Stella et al., [36, 37] attribute this behaviour to non-instantaneous protonation and 
deprotonation of phenylbutazone, and identify the sole hydrogen atom on the central 5-
membered ring as the proton that is donated. Phenylbutazone is therefore designated a carbon 
acid, and its pKa has been determined to lie between 4.50-4.70. 
 
1.3.2  Crystal Forms - Summary of Literature Findings 
 
Data on the polymorphic form that results upon crystallization of phenylbutazone from a 
particular solvent under atmospheric conditions have been published by a number of groups 
of researchers, in the context of uncovering new polymorphic and solvated forms. Grinding 
and spray drying studies have brought to light additional crystal forms. The existence of 
between 3 & 6 polymorphs has been claimed, however a complete crystal structure of only 
one of these forms has been deposited in the Cambridge Structural Database, CSD, [38]; this 
structure corresponds to the polymorph commonly referred to as the alpha form. Several 
solvate structures have also been deposited on the CSD. 18 
A second structure of the alpha form has also been published, [39], however a literature 
search revealed no structure solutions of the remaining polymorphs, including the commonly 
encountered polymorphs referred to as the delta and beta forms. The previous structure 
solutions of the alpha form and all solvate structure solutions were achieved by single crystal 
X-ray diffraction, SCXRD. The polymorphs identified by individual research groups are 
shown in the following table. In many of the earlier papers, alternative designations had been 
used for the polymorph in question; these designations have been superceded by the widely-
adopted Greek letter nomenclature, which is shown in the column headings. The availability 
of structure solutions is mentioned. In most cases, the primary means of identification of 
polymorphic form is PXRD, and this has been indicated.  
Table 1 - Identification of Phenylbutazone Polymorphs by Citation 
 
Group  Form ʱ  Form β  Form δ  Other 
Polymorphs 
Solvates 






   




  “Form I”(iso-butanol) 
& “Form 
2”(cyclohexane) 
Singh & Vijayan, 1977   CS         









   
Müller, 1978   PXRD  PXRD  PXRD  Gamma  iso-butanol, 
cyclohexane 










Matsuda et al.,1982   PXRD  PXRD  PXRD  Epsilon
sp   





Paradies, 1987  CS         











PXRD = identified by PXRD, DSC = identified by DSC, CS = crystal structure solution by SCXRD,  
sp = formed by spray-drying, gr = formed by grinding,  
†the two DSC peaks correspond to form alpha, however Matsuda et al. query the identity of this crystal form 19 
The methods used to identify polymorphs and solvates are described in detail in Chapter 2. In 
common with most of the cited literature references, powder X-ray diffraction was the 
primary technique used to distinguish between crystal forms during this investigation. The 
PXRD patterns of the various polymorphs mentioned in the literature were compiled, and 
stick diagrams were prepared for subsequent polymorph and solvate identification.  
1.3.2.1  Polymorphs 
 
Reference PXRD patterns of the polymorphs alpha, beta and delta were collected both in-
house and on beam-line I11 of Diamond Light Source at Didcot, Oxfordshire. For the 
purposes of comparison, peak intensities were recalculated on a scale of zero to one, scaled in 
relation to the intensity of the maximum peak after subtraction of background counts; 
(Appendix 5).  Good agreement was found between the patterns of the alpha, beta and delta 
forms collected during this investigation and PXRD patterns obtained from the literature; see 
following figures.  
Figure 2 - Major Peak Comparison of Delta Form 
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Figure 3 - Major Peak Comparison of Alpha Form 
 
 
Figure 4 - Major Peak Comparison of Beta Form  
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Besides the three widely identified polymorphs, alpha, beta & delta, form names have been 
proposed for a number of other putative polymorphs. The most notable of these was obtained 
by a research team in Kobe, Japan, [23] using a spray-drying technique in which the new 
polymorph was produced concomitantly with the beta and delta forms. Matsuda et al. used 
the designation epsilon, ε, to refer to this new form. First mention of this form is made in a 
paper from this group dating from 1980, [21]. 
In 1988 a Japanese group at Showa University in Tokyo, [20], revealed that prolonged 
grinding of phenylbutazone could also bring about the formation of form epsilon. In addition 
the same paper by Matsumoto et al. reported that the grinding procedure first gave rise to an 
intermediate form, to which they assigned the designation zeta, δ; the existence of this form 
has not been confirmed by other research groups subsequently. 
Solely on the basis of thermal analysis data, Müller also proposes the existence of a new 
form, which he designates gamma, γ. From crystallizations employing solely the solvent n-
heptane, Tuladhar presents analytical data for 5 distinct crystal forms including the 
polymorphs alpha, beta and delta. Basing his conclusions primarily on DSC results, he 
identifies one of the two new forms as the polymorph designated form gamma.  
Efforts to reproduce the novel crystal forms encountered by Tuladhar using n-heptane were 
not successful. Storage of an n-heptane solution of phenylbutazone for a number of weeks 
was observed to give rise to an amorphate. However, fresh solutions crystallized to give 
samples of known polymorphs; frequently in concomitant mixtures. The polymorphs most 
frequently obtained when using n-heptane were alpha/delta mixtures, but the beta form was 
also found to be present in certain mixtures prepared at above-ambient temperature. 
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1.3.2.2  Solvates 
The crystal structures of phenylbutazone’s solvates have been investigated more successfully 
than those of its polymorphs. Structures of six solvates with the solvents listed below have 
been deposited into the Cambridge Structural Database by Hosokawa et al, [13]. The 
structures of the solvates with the first five of the solvents in this list have been determined 
by SCXRD and found to be monoclinic with space-group C2/c; (Table 13): 
  benzene 
  cyclohexane 
  1,4-dioxane 
  tetrahydrofuran 




In addition there are literature reports of the formation of a solvate with iso-butanol, [16]. 
During a solvent screening carried as part of this investigation, four further solvates have 
been identified. These were formed with: 
  cyclohexanone 
  cyclopentanone 
  methyl-tertiary-butylether 
  propylene carbonate 
 
In order to confirm the presence of solvent in the new crystal forms, nuclear magnetic 
resonance spectra; (Section 2.2.4), were collected for each of the four new solvates. A 
                                                           
3 Only unit cell dimensions and space-group have been determined for this solvate. 23 
comparison of peak multiples and strengths between NMR spectra of pure phenylbutazone 
and those of certain of its solvates is shown in the following table.  
An indication of the strength of the central peak, (s = strong, m = medium, w = weak), is 
given beside each peak multiple. 
























    (ppm)                         
1  CH3  0.90  Triplet  s  Triplet  s  Quartet  m  Triplet  s  Quartet  s  Triplet  s 
2  CH2  1.36  Quartet  w  Quartet  w  Quartet  w  Quartet  m  Quartet  m  Triplet  w 
3  CH2  1.48  Quartet
n  w  Quartet  w  Quartet
n  w  Triplet  m  Triplet  m  Quartet
n  s 
4  CH2  2.08  Quartet
n  w  Quartet
n  w  Quartet
n  w  Quartet
n  m  Quartet
n  m  Quartet
n  w 
5  CH  3.38  Quartet
n  w  Triplet  m  Triplet  w  Quartet
n  m  Quartet
n  m  Triplet  w 
6  Phenyl, 
para  7.17  Quartet
n  m  Quartet
n  m  Quartet
n  w  Quartet
n  m  Quartet
n  m  Quartet
n  w 




n  s  Quartet
n  s  Quartet
n  s  Quartet
n  s  Quartet
n  s  Quartet
n  m 
n denotes that the number of recorded peaks was higher than a quartet 
 
Although groupings of as many as nine peaks are observed, for reasons of clarity, multiplets 
of four or more peaks are designated as quartets. Chemical shift positions for the various 
phenylbutazone moieties in the reference spectrum are in close agreement with those 
appearing in spectra of the various solvated forms. Consistency of relative peak intensities is 
generally good also.  
The size of the peak multiple for a particular moiety is observed to vary somewhat between 
individual crystal forms. For position 5, which has been identified as phenylbutazone’s 
proton donating group, a markedly lower number of peaks are present in the samples of the 24 
solvates with tetrahydrofuran, methyl-tert.-butylyether and propylene carbonate; only a triplet 
is observed in each case. For position 3, the converse is observed; the cyclic-ketone solvate 
spectra exhibit a smaller multiplet than the remaining solvates.  
The structures of the four new solvates  were investigated by PXRD and SCXRD.  Structure 
solutions of the solvates with methyl-tertiary-butylether and propylene carbonate were 
determined successfully; (Section 3.2.2), and were found to be monoclinic with space-group 
C2/c in common with five solvates examined by Hosokawa et al.. PXRD patterns of the four 
new solvates are shown in the following figures. 
Figure 5 - PXRD Patterns of Two New Solvates with Space Group C2/c 
 
The PXRD patterns of the solvates with the two cyclic-ketones share near identical major 
PXRD peak positions, suggesting that these two solvates have essentially identical crystal 
structures. Their PXRD patterns are also very similar to that of the solvate with propylene 
carbonate shown above.  25 





In the course of the present investigation, several samples of the solvate with tetrahydrofuran 
were prepared. Good reproducibility of the PXRD pattern was observed between different 
batches prepared in-house, however this PXRD pattern does not resemble that of Hosokawa 
et al.. Further investigation of this solvate was carried out, and the results are presented in 
Section 3.2.2.2. 
1.3.3  Making the Different Crystal Forms 
 
The preparation of the solvates of phenylbutazone did not entail special crystallization 
procedures. The alpha and delta polymorphs are readily obtained by conventional solvent 
crystallization techniques, also. Concomitant mixtures of these two polymorphs often occur. 
Results of evaporative crystallizations in a range of solvents are displayed in Table 14, where 
                                                           
4 Patterns have been normalized to the same maximum intensity. 26 
experiments intended to yield pure samples of the alpha, beta and delta forms have been 
summarized also.  
It proved straightforward to produce pure batches of the alpha form by solvent 
recrystallization using either the delta or beta form as starting material. However production 
of pure delta form from solution was not reproducible. Pure delta form was obtained reliably 
by isothermal heating of the solid alpha and beta forms below the melting temperature of the 
delta form, but above their respective transition temperatures; (Chapter 5). 
The beta form is obtained reproducibly as a precipitate by the addition of water, in which 
phenylbutazone is insoluble, to solutions in a number of organic solvents; the use of water 
miscible solvents such as methanol and ethanol is most frequently described. The precipitate, 
which is formed exothermically, often contains amounts of other polymorphs, most notably 
the delta form. Rapid stirring of the precipitation mixture has been found to assist the 
formation of a high proportion of the beta form, and investigation of the influence of the 
water:solvent ratio is also discussed in Section 4.4.3.3. It has been possible to isolate pure 
beta form crystals at the edge of crystallization samples formed by evaporation from organic 
solvent without the use of water. In addition the beta form is encountered in concomitant 
mixtures with the other polymorphs after evaporative crystallization in single solvents, 
particularly when this crystallization occurs at above-ambient temperatures.  
The zeta and epsilon forms reported in the literature are produced by extended grinding, 
presumably through the use of an automated mill. They were not encountered during the 
course of solvent evaporations with single solvents or binary solvent mixtures. Existence of 
the gamma polymorph could not be confirmed either. 27 
2  Analytical Techniques Employed 
 
In this investigation the principal method used to identify the crystal form present has been 
powder X-ray diffraction. Borka and Haleblian, [41] , conclude that, “X-ray diffraction 
methods on single crystals or powdered samples almost never fail due to their outstanding 
ability of detecting differences in crystal structures”, whereas they consider infrared 
spectrometry merely as, “a sensitive, but not necessarily infallible method in identifying 
polymorphs”. PXRD patterns are typically included in patent filings of drug molecules in the 
United Kingdom.  
Reference infrared spectra of the alpha, beta and delta polymorphs of phenylbutazone were 
collected, and are included as an appendix, however this technique was not relied upon for 
day to day polymorph identification. 
Differential scanning calorimetry finds regular use in the pharmaceutical industry to identify 
polymorphic forms, [42-45], particularly those of less crystalline substances such as waxes. 
In the case of phenylbutazone, which undergoes transitions in polymorphic form that are 
invisible to the naked eye, DSC is a very revealing technique. Nonetheless DSC was not 
employed as a primary means of polymorph identification. 
 
2.1   Distinguishing between Polymorphs & Solvates 
 
Powder X-ray diffraction served as the primary means, by which to identify solvated crystal 
forms as well as polymorphs. Upon obtaining a PXRD pattern whose peak positions did not 
correspond to those of known or putative polymorphs, confirmation of the presence of a 
solvated form was carried out by the methods described overleaf: 28 
a. 
1H Nuclear Magnetic Resonance Spectroscopy provides chemical shifts and peak 
intensity ratios that are characteristic of the substances present in a sample. The 
presence and identity of a given solvent is clearly identifiable, where reference 
spectra are available, or 
1H chemical shift data have been collected for the solvent in 
question. 
1H Nuclear Magnetic Resonance spectroscopy also provides a crosscheck 
for the presence of side products in mixtures, where there is the likelihood of 
chemical reaction.   
b.  Thermogravimetric Analysis shows up weight loss associated with desolvation, and 
provides corroboration of a hypothesis that a crystal form is solvated. In addition it 
provides insight into the manner, in which solvent is released from a known solvate. 
TGA may also be used for quantitative estimation of the ratio of solvent to solute, 
important information for crystal structure determination. However this technique is 
prone to error in cases where not all solvent is integrally bound-up in the crystal 
lattice; for example: 
  solvates of high-boiling solvents, which retain surface solvent at ambient 
temperatures to give “wet” powder samples 
  solvates of volatile solvents, in which the solvent molecules are able to escape 
from all or part of the lattice prior to thermal decomposition of the crystal 
c.  Isothermal Heating of a sample in an oven at a temperature slightly below its 
melting point, followed by a further PXRD scan, shows up the presence of solid-state 
transitions between polymorphs; (Chapter 5). Many solvated forms also exhibit a 
crystal form change upon heating; the most common transition is solvent expulsion 
leading to formation of a known polymorph. 29 
d.  Single Crystal Diffractometry can confirm the presence of solvent molecules in 
crystal structures, assuming that the solvent molecules are readily distinguishable on 
the electron density map. Positive identification may be hampered by a tendency of 
solvent molecules to take up positions in the crystal lattice that are not entirely 
regular; a phenomenon often referred to as disorder. 
 
The following decision tree summarises the chain of testing steps, which was used in this 
investigation to arrive at a conclusion about the nature of an unknown crystal form:  
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2.2  Description of Individual Analytical Techniques 
 
2.2.1  Visual Melting Point Determination 
 
Heating of samples in glass capillaries was carried out in an electrically heated melting point 
apparatus equipped with a mercury thermometer. Samples were warmed gradually at a 
temperature gradient of under 5K/minute, until a change from the solid to the liquid state 
could be confirmed by visual inspection of the sample within the capillary. 
 
2.2.2  Powder X-ray Diffraction, (PXRD) 
 
Sample particle sizes were reduced by careful grinding using pestle and mortar, and sieved in 
order to reduce texture and to help avoid preferred orientation. Unless otherwise specified, 
data were collected in conditions of ambient temperature and pressure.  
In all cases raw data consisting of 2theta, intensity and error measurements were exported 
into Microsoft Excel
®, in which various data processing tasks could be accomplished; e.g. 
phase identification, background count analysis and selection of peaks for unit cell indexing. 
Where necessary, rebinning of datasets into different 2theta step sizes was carried out either 
directly in Excel
®, or in Matlab
®, from where rebinned data were re-exported into Excel
®.  
Comparison charts, showing scaled reference peak positions, were used extensively to 
identify the polymorphs present in crystallization batches. In most cases they were capable of 
dispelling ambiguity, but not always. For example, the newly identified solvate of 
phenylbutazone with methyl-tertiary-butylether has a peak at 2θ = 8.3ﾰ (CuKʱ radiation). This 
peak position happens to be nearly identical to that of the largest peak in the diffraction 
pattern of the beta form; 2θ = 8.28° (CuKʱ radiation).  32 
Scaling of the reference peaks is inconclusive in this case; the breadth of the largest peak at 
2θ = 6.9ﾰ does not preclude the possibility that some beta form is present.  
 




In-house diffraction experiments were carried out on two diffractometers; one with flat plate 
geometry, the other with transmission geometry. Off-site access was obtained to Station I11 
at the Diamond Light Source, which is equipped with a high-speed, powder diffractometer.  
The capabilities of these instruments are outlined in the following sub-sections. 
                                                           
5 Average background count has been subtracted before scaling. 33 
2.2.2.1  Flat Plate Diffractometer, Siemens D500 
 
The following operating conditions were maintained throughout; transformer voltage 30kV 
and X-ray tube output current of 40mA, to generate radiation from a  CuKʱ X-ray tube 
Diffraction patterns collected on this instrument typically display low, linear background 
counts. The device is periodically calibrated with a quartz test sample to correct for 2theta 
zero drift. This diffractometer was employed for routine polymorph identification.  
 
2.2.2.2  Transmission Geometry Diffractometer, Stoe Stadi
®-P 
 
A transformer voltage of 30kV and X-ray tube output current of 40mA were maintained 
throughout. CuKʱ and CoKʱ X-ray tubes were employed. 
This instrument may be used with a stationary, wide-angle detector capable of collecting a 
2theta range of 40° in a single data collection period of as little as 5 minutes. For more 
detailed scans, a moving detector is used; this steps around the desired 2theta arc, pausing to 
collect X-ray counts over discrete time intervals.  
The moving detector used on the Stoe Stadi
®-P diffractometer has more than one channel; i.e. 
data counts are collected at more than one 2theta position simultaneously. In four channel 
detection, a typical operating mode, the final count reading comprises the sum of the readings 
at four different step positions, as recorded by each of the four channels individually.  
This instrument is also equipped with a liquid nitrogen jet that incorporates a heating element 
and thermostatic control, enabling the sample to be cooled or heated isothermally across a 
temperature range of 100-500K.  
 34 
2.2.2.3  Multimode Diffractometer, Station I11, Diamond Light Source 
 
 
This apparatus utilizes a 
monochromatic synchrotron beam, λ 
= 0.8269Å, whose intensity varies 
over time; (see figure opposite). 
Much lower counting times are 
needed to reach desired count levels, 
when compared with the in-house 
diffractometers described earlier. 
 
Figure 9 - Beam Delivery at Station I11 
The diffractometer, [46], uses a moving detector, and can collect a dataset across a 2theta 
range of 180° with step intervals of 0.01° in less than an hour. It is able to operate in flat-plate 
or transmission geometry modes. In this instance, data were collected exclusively in 
transmission mode, and samples were contained in capillaries. In contrast to the Stoe Stadi-P, 
the radiation beam is directed at the sample using parallel beam optics. 
The data from each of the detectors were corrected for relative 2theta position, relative 
efficiency, and for synchrotron beam decay, before being merged into a single diffraction 
dataset. This equipment reveals peak overlaps in diffraction patterns collected on 
conventional diffractometers, greatly facilitating determination of the unit cell and space-
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2.2.3  Single Crystal X-ray Diffraction, (SCXRD) 
 
X-ray diffraction data of single crystals were collected on a Bruker four circle diffractometer 
equipped with a Smart Apex
® area detector consisting of a charge-coupled device. The X-ray 
radiation employed in this diffractometer is MoKʱ, (λ = 0.7103Å). Control of all instrument 
parameters is exercised by the Bruker Saint
® software package, which also performs data 
reduction. This suite incorporates XPrep and XShell modules for structure solution, as well as 
a version of Shelx for solution refinement; the suite is referred to collectively as Shelxtl
®. All 
single crystal datasets were collected at 150K. This temperature is maintained by a liquid 
nitrogen flow, which is controlled by means of a Windows
® PC with an appropriate software 
interface. Data collection takes place in two distinct steps: 
  An orientation matrix consisting of about 60 frames is collected, from which 
automatic unit cell determination is attempted; total duration, 0.5-2 hours. 
  A full dataset consisting of approximately 1800 frames is collected; total duration, 7-
15 hours. 
The results of the unit cell determination step were used to reach a decision, whether to 
proceed with the collection of a full dataset. In general, the absence of a reasonable set of unit 
cell dimensions from the first step militated against collection of a full dataset. It was far 
from unusual to test half a dozen crystals in the first step, before encountering a specimen 
whose results augured well enough to proceed to the second step. 
The diffractometer’s preset angle selections were employed in both steps.  
 36 
2.2.4 
1H Nuclear Magnetic Resonance Spectroscopy, (NMR) 
 
Only 
1H NMR spectra were collected. Samples were dissolved in CDCl3, and examined in a 
Bruker, Avance500
® spectrometer. Calibration is performed using solvent residual peaks; 
7.26ppm for CDCl3. Data processing is carried out using Bruker Xwin
® NMR software.  
A reference spectrum was prepared for pure phenylbutazone, and is displayed in Appendix 4. 
The presence of multiplet peak positions is indicated by shading of groups of peaks. These 
reference data were used to match chemical shift positions in subsequent spectra; for example 
those collected from samples of phenylbutazone’s solvates. In many cases solvent 
components and residues could be identified using literature data, [47]. In those cases where 
literature chemical shift data were not located, a reference spectrum was prepared for the 
solvent under investigation.  
The relative positions of the hydrogen atoms on the alkyl chain and the phenyl groups may be 
deduced from the chemical shifts of the various functional groups contained in similar 
molecules that are present in literature listings; e.g. in spectra of common solvents. For 
phenylbutazone the chemical shifts of the phenyl group hydrogen atoms are in the vicinity of 
7ppm, whereas the alkyl hydrogen atoms are in the region of 0.8 to 3.5ppm.  
NMR spectrum analyses of phenylbutazone are available from literature sources, [7, 48]. The 
in-house reference spectrum is in good agreement with the analysis of Tanaka et al. with only 
one exception; the peak at 1.57ppm. This most likely indicates the presence of a trace of 
water, whose chemical shift in CDCl3 is measured at 1.56 ppm by Gottlieb et al.. The 
outlying peak at 7.25ppm is very probably that of the solvent residual. The chemical shifts 
are marked according to the moiety to which they pertain, and given a magnitude (strong, 
medium, weak, trace) according to the size of the central peak in the multiplet, [49].  37 
2.2.5  Differential Scanning Calorimetry, (DSC) & 
Thermogravimetric Analysis, (TGA) 
 
A Netzsch Jupiter
® combined DSC & TGA was used. In most cases, both thermogravimetric 
and calorimetric measurements were carried out simultaneously. This equipment is able to 
carry out consecutive isothermal heating and constant-gradient temperature increase steps. 
Reference DSC scans of the alpha, beta and delta polymorphs are shown in Appendix 2.  
Thermogravimetric Analysis was used, in certain instances, when the presence of a solvate 
was suspected. The TGA is equipped with a precision balance inside the furnace, enabling 
high-accuracy measurement of weight changes during heating cycles. Weight loss during the 
TGA scan is an indicator of the presence of solvent; the heating of pure phenylbutazone was 
not accompanied by weight loss; i.e. no tendency towards sublimation was confirmed during 
heating in the solid phase, and no discernable weight loss through vapourisation occurred 
after melting. Some drift in scale readings was encountered in TGA measurements, and zero 
correction runs with no sample in the pan were carried out in order to confirm that drift was 
the result of buoyancy effects. 
 
2.2.6  Infrared Spectrometry, (IR)  
 
Infrared spectra were collected across a wavenumber range of 400-4000cm
-1 at a resolution 
of 4 cm
-1, using a Shimadzu FTIR-8700, Fourier Transform Spectrometer. KBr sample disks 
were prepared using a Specac press, capable of applying a pressure equivalent to a weight of 
15 tons on the sample mixture. Data processing was carried out with Shimadzu’s Hyper
® I.R. 
personal computer software package, which is based on Spectacle
® by LabControl GmbH. 
Reference IR spectra of the alpha, beta and delta forms of phenylbutazone are shown in 
Appendix 3. 38 
3  Structure Determination of Polymorphs and Solvates 
 
3.1  Indexing of Powder Diffraction Data 
Indexing of powder diffraction patterns seeks to match observed interplanar distances, dhkl, 
with the appropriate reflection plane, h,k,l, in simultaneous solution sets that fit the observed 
data with as high a figure of merit, FOM, as possible in order to determine the most probable 
unit cell dimensions for a crystal form. Peak intensity information is generally not required.  
 
Figure 10 - Generalized Parallelepiped Representation of the Unit Cell
6 
      
 
Figure 11 - H,K,L Indexing Example - Planes of a Cubic Lattice
7 
 
                                                           
6 Reproduced from Pecharsky & Zavalij, Fundamentals of Powder Diffraction, 2005, Springer, New York,  p6. 
7 Reproduced from Pecharsky & Zavalij, Fundamentals of Powder Diffraction, 2005, Springer, New York, p47. 39 
The geometrical relationships between observed d-spacings and their associated plane indices 
are provided in a variety of different text books on crystallography, [50, 51].  For triclinic, 
monoclinic and orthorhombic unit cells, the crystal systems encountered during this 
investigation, these relationships are shown below: 
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Equation 2 - Monoclinic d-Spacing, (angle ß unique) 
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Equation 3 - Orthorhombic d-Spacing 
 
2 2 2




d a b c
    
 
Where: 
h = Index number of plane along x-axis 
k = Index number of plane along y-axis 
l = Index number of plane along z-axis 
d = Perpendicular distance between a plane with index, hkl, and the origin. 
a, b and c represent lengths of dimensions of the unit cell; 
ʱ, β, and γ represent the angles between the cell lengths a, b and c;  
     40 
In most cases the equality for which simultaneous solutions are sought is expressed in terms 
of reciprocal lattice points, the points which correspond to individual planes, when the planes 
of the crystal structure in direct space are projected into reciprocal space. 
 
Figure 12 - Example of a Reciprocal Lattice
8 
 
The reciprocal unit cell dimensions, which are denoted by an asterisk, have vector properties 
and are derived from the direct space unit cell dimensions as follows: a* = 1/a, b* = 1/b, c* = 
1/c, and d* = 1/d. The distance, d*, from the origin to a reciprocal lattice point, h,k,l, is given 
vectorially by: 
Equation 4 - General Expression for Reciprocal Lattice d-Spacing 
 
* * * *
hkl d ha kb lc     
                                                           
8 Reproduced from Pecharsky & Zavalij, Fundamentals of Powder Diffraction, 2005, Springer, New York, p167.  
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The quantity, d*hkl, may equally well be expressed in scalar terms analogously to the three 
equations for the direct space interplanar distance shown earlier. Typically the symbol Q is 
used to denote the value of 
2 *
hkl d : 
Equation 5 - Triclinic Reciprocal Lattice d-Spacing 
 
     
2 22 2 * * * * * * * * * * * * * 2 cos 2 cos 2 cos hkl Q d ha kb lc hka b hla c klb c            
 
Equation 6 - Monoclinic Reciprocal Lattice d-Spacing, (angle ß unique) 
 
     
2 2 2 2 * * * * * * * 2 cos hkl Q d ha kb lc hla c         
 
Equation 7 - Orthorhombic Reciprocal Lattice d-Spacing 
 
     
2 2 2 2 * * * *
hkl Q d ha kb lc      
 
Indexing was carried out on a Windows
® personal computer using software designed 
exclusively for this purpose. A recent survey of powder X-ray diffraction techniques by The 
Royal Society of Chemistry, [52], catalogues crystallographic software packages designed for 
unit cell indexing. An overview of the differences in the methods by which these indexing 
programs search for unit cell parameters is provided in the IUCr’s 2002 monograph on 
structure determination from PXRD data, [53]. 
The software employed in this investigation was the collection of indexing programs 
contained in the Crysfire suite, which is available from the website of the Collaborative 
Computational Project 14, [54].  42 
The following programs included in this suite were used to search for unit cell solutions from 
PXRD peak sets:  
  ITO 
  TREOR 
  KOHL 
  LZON 
  DICVOL 
  FJZN 
 
Q-matching to observed peaks forms the basis for the search algorithms in ITO, TREOR, 
DICVOL and in the more recent indexing program, KOHL, [55, 56].  
For all the programs included in Crysfire, common figure of merit values are reported in a 
summary output of solutions. For each solution the first reported statistic is the number of 
peak positions or “lines” that were included in the simultaneous solution set.  
The maximum value, 20 lines indexed, indicates that a match between 20 calculated and 
observed index lines was found within the prescribed tolerance for the 2theta values (or d-
spacings). 
 Most programs in Crysfire caution against the adoption of solutions in which fewer than 17-
18 lines have been successfully matched to a set of index values for a particular unit cell 
solution. 
The bases of the most common FOMs are as follows: 








  43 
Where: 
Q20 = Q value of 20
th observed and indexed line 
N20 = Number of calculated reflections up to the d value corresponding to Q20 
<Q> = Average discrepancy between observed and calculated Q values for these 20 lines 
 















θg = Limit value of 2θ for individual search 
<|Δ2θ|> = Average value of the modulus of differences between observed and calculated 2θ 
N(θg) = Number of different calculated Q values up to θg 
N = Number of observed lines below θg 
 
The higher the values of the FOMs, the closer the match between individual observed and 
calculated values of 2theta (or d-spacing). For M20 values of 10 or higher constitute a good 
match, whereas for FN values of 20-60 indicate a solution with a high confidence level. 
 
3.1.1  Peak Input Selection for PXRD Indexing 
 
The importance of high quality PXRD data for accurate unit cell determination is stressed by 
many texts on crystallography. Synchrotron PXRD data generally offer very clear peak 
information, and are ideal for indexing purposes. Another method to improve peak selection 
is through the use of composite patterns comprised of several patterns of the same sample, in 
which count numbers at each 2theta step are added to give a cumulative pattern. 44 
Composite patterns allow the effects of background counts to be averaged across several 
datasets. If the assumption can be made that background fluctuations occur randomly above 
or below a mean number of background counts for an individual diffraction dataset, then 
addition of multiple diffraction datasets for the same sample results in an averaging out of 
background fluctuations. This leads to a flatter overall background, enabling small diffraction 
peaks to be resolved from background noise with greater confidence. Analysis of background 
count information and discussion of its statistical treatment is provided in Appendix 5. 
The following patterns show an individual plot of one PXRD pattern and a composite plot of 
several PXRD patterns of the same sample of phenylbutazone collected at Station I11 of the 
Diamond synchrotron facility. 
Figure 13 – Example of Improved Resolution from Summation of Repeated PXRD Scans 
 
When carrying out pattern summation, care was taken to be sure that underlying peak 
positions of the individual patterns did not show marked deviations which, upon super-
imposition of additional patterns, would obscure the underlying peak information.  45 
3.2  Indexing of  Phenylbutazone Crystal Forms 
 
When examining sets of possible unit cell dimensions, solutions from higher symmetry 
crystal systems were favoured, assuming that their figures of merit reached acceptable values, 
and provided that the suggested unit cell dimensions did not exceed sensible limits. Higher 
symmetry than an orthorhombic lattice, [57], was not anticipated, however. Knowledge of the 
unit cell volume of the alpha form of phenylbutazone was one indicator of likely unit cell 
dimensions of other crystal forms, but the possibility of discovering additional symmetries in 
unit cells of double or quadruple the size was borne in mind.  
In general, it proved difficult to arrive at firm conclusions about unit cell solutions of 
phenylbutazone crystal forms from Crysfire output alone. Unlike the unit cell determination 
example shown by Ladd and Palmer, [50], there were very few instances in which two  
separate programs in the suite arrived at the same solution, making the identification of a 
single set of unit cell dimensions difficult, unless a priori structural information was to hand. 
Crysfire’s output has been formatted to integrate with Chekcell, a program that validates 
individual solutions, and which runs a comprehensive set of space-group tests in order to 
arrive at suggestions of the likeliest unit cells and space-groups for a given powder pattern. 
Chekcell also includes search routines for sub-cells and super-cells of an individual unit cell 
solution, and permits trials of different space-group selections on each unit cell solution 
proposed. This program was used extensively to help narrow down the selection of probable 
unit cell dimensions. 
In order to test the robustness of solution sets, the Crysfire programs were also run iteratively 
on slightly modified sets of peak inputs with the objective of identifying solutions that 
withstood specific minor peak omissions.  46 
Partly owing to the inconclusive nature of the indexing results, manual checks of individual 
unit cell solutions were carried out. General listings of index positions with no observed 
extinction conditions were calculated using a spreadsheet prepared for this purpose.  
Access was also obtained to the Fortran program, Dragon, [58], which not only calculates 
index positions for a given unit cell in a particular crystal system, but which also applies 
extinction conditions for individual space-groups. Dragon output data can readily be exported 
into spreadsheets, where a simple, graphical check of the validity of proposed indexing 
solutions can be carried out.  
The results of unit cell determination of individual polymorphs and solvates of 
phenylbutazone are described in the following sub-sections. 
 
3.2.1  Polymorphs 
3.2.1.1  Alpha 
 





















Singh & Vijayan, 1977 
(Single Crystal 
2300 Reflections) 











  3348.57 
Paradies, 1987 
(Single Crystal - 296K 
4977 Reflections) 











  3347.20 
Targett & Cockcroft, 
2008 (Single Crystal - 
150K 
7765 Reflections) 





(±0.005)  90  108.068 
(±0.003)  90  3240.40 
Targett & Cockcroft, 
2008 (PXRD – 298K –  
20 lines, FOM 30.9) 
P21/c  21.719  5.826  27.882  90  108.066  90  3354.05 
 
                                                           
9 In the case of single crystal diffraction results, the estimated error is also provided in parentheses. 47 
The preceding table summarizes the unit cell dimensions of the alpha form, including the 
solutions of Singh & Vijayan and Paradies; these results were obtained from single crystal X-
ray diffraction experiments. In this investigation the alpha form’s unit cell was determined 
first by single crystal diffraction as outlined in the next section. Subsequently a very similar 
solution was obtained from the synchrotron powder diffraction data collected at Diamond 
using the indexing program, KOHL. The slightly larger size of the unit cell calculated from 
PXRD data is most likely attributable to the higher temperature at which the data were 
collected.  
Refinement of the unit cell was carried out on the single crystal dataset; (Section 3.5.2). The 
synchrotron PXRD pattern revealed peak overlaps present in the literature PXRD patterns 
collected on standard X-ray diffraction equipment; (Figure 2). Both the synchrotron PXRD 
pattern and a listing of index positions are shown in Appendix 1.  
 
3.2.1.2  Beta 
 
The unit cell dimensions of the beta form have not been reported in the literature. In this 
investigation, beta form powder diffraction patterns displayed larger variations in peak 
positions than those encountered in PXRD datasets of the alpha and delta forms.  
It seems reasonable to infer that the beta form is the least ordered crystal structure among the 
three commonly encountered forms. This conclusion is supported by comparison of the 
baselines of the various polymorphs; the beta form pattern has a less uniform baseline than 
the other two polymorphs.  
A reference PXRD pattern of the beta form was collected at Diamond, however this revealed 
the presence of a small proportion of the delta polymorph. Delta peaks were extracted from 
the data, before compilation of input peaks for unit cell determination using Crysfire.  48 
Indexing was further complicated by a difference in the low angle peak positions in PXRD 
patterns collected in-house and those collected at Diamond Light Source. In-house data 
consistently indicated the presence of a very small peak at 2θ = 4.15ﾰ. However this peak was 
absent from the synchrotron PXRD patterns and from literature patterns of the beta form. 
Indexing was carried out both with and without the peak at 2θ = 4.15ﾰ included. 
With the peak at 2θ = 4.15ﾰ included, Crysfire yielded unit cell solutions that were either 
triclinic (space-group Pı or Pī) or monoclinic (space-group P21); the former outnumbering the 
latter by a factor of about 5.  Unit cell sizes lay between
10 1800-4400Å
3 for the triclinic 
solutions and between 4000-6000Å
3 for the monoclinic solutions. 
Without the peak at 2θ = 4.15ﾰ, only one monoclinic solution was found; unit cell size of 
4000Å
3. A near identical monoclinic solution could also be found when the 2θ = 4.15ﾰ peak 
was included, however only 16 out of 20 observed peak positions are matched in this 
solution; the 2θ = 4.15ﾰ peak was not among the matched peaks. 
Leaving aside the issue of inclusion or exclusion of the 2θ = 4.15ﾰ peak, it became apparent 
that even very slight variations in the peak inputs led to changes in the dimensions of triclinic 
solution sets. Furthermore only one solution among over 40 alternatives was encountered, on 
which two programs agreed.  
In view of these difficulties, indexing solutions of the beta form are presented with only low 
confidence. The most probable solutions are shown in the table that follows: 
 
 
                                                           
10 Excludes one outlying triclinic solution at 7930Å
3. 49 





















Lines Indexed 20, FOM 
10 
13.8  15.3  11.7  113  86  116  2030 
*Triclinic, P1 
Lines Indexed 20, FOM 
10 
12.5  13.7  12.1  111  105  95  1836 
Triclinic,  
Lines Indexed 19, FOM 8  6.9  12.8  22.2  81  77  91  1887 
Monoclinic, P21/c  
Lines Indexed 16, FOM 8 
 
14.1  23.5  13.6  90  117  90  4000-
4040
† 
†Several variations of this solution were found, differing by less than 0.2Å in dimension 
* Excludes peak at 2θ = 4.15ﾰ 
 
 
3.2.1.3  Delta 
 
Similarly to the beta form, a search of the literature did not yield any indications of the unit 
cell dimensions of the delta form of phenylbutazone. Synchrotron PXRD data of the pure 
delta form were obtained at Diamond; (Appendix 1). 
Although not entirely conclusive, the results of Crysfire indexing of the delta form pattern 
may be presented with much higher confidence. The KOHL output was again the most 
illuminating. It indicates that the unit cell is probably orthorhombic with two long dimensions 
of approximately 34Å each and a shorter third dimension of between 5-10Å. However no 
fewer than 9 variations of this solution were located, differing only in their shortest cell 
dimension; (20 lines indexed, FOM ~ 20). Initially the smallest cell volume in this family that 
Kohl located was 8588Å
3 which corresponds to c = 7.22Å. Upon varying the choice of input 
peaks, the solution with c = 11.505Å established itself as the most likely, however 
performing a sub-cell search on this solution in Chekcell revealed a favourable solution with 
dimension, c = 5.753Å, half the size of the most robust cell solution, and sharing 50 
approximately the same short dimension as the alpha form. Reassuringly the same solution of 
6837Å
3, possessing a short dimension of 5.75Å, could also be determined separately using 
the indexing program ITO. 























 20 lines indexed, FOM 
20.4 
32  34.825  34.135  11.505  90  90  90  13677 
Orthorhombic 
 20 lines indexed, FOM - 
subcell 
16  34.816  34.147  5.751  90  90  90  6837 
 
Identification of the space-group symmetry was carried out using the automatic space-group 
determination facility in Expo2004, which reports the fit to a particular space-group with its 
own figure of merit calculation, [59]. 
For the unit cell solution with Z value of 32, the highest figure of merit recorded by Expo was 
0.20; this was achieved in the space-group P212121. Four further space-group alternatives 
were determined to have FOM values between 0.02-0.06. For the unit cell solution with Z 
value of 16, fifteen different space-groups had figures of merit between 0.01-0.10; the highest 
amounted to 0.08.  
As is discussed later on, more reflection conditions are observed than the three general 
conditions of space-group P212121; h00 = 2n, 0k0 = 2n, 00l = 2n.  Primarily for this reason, 
the subcell option is favoured, and subsequent analysis is based upon the assumption that Z = 
16 is the correct value. This leads to a calculated density of 1.20g/cm
3 compared to a value of 
1.26g/cm
3 for the alpha form.  51 
A listing of the most probable space-groups for the unit cell size 6837Å
3 was obtained from 
Expo. In depth space-group testing was then carried out in the following manner: 
 
a)  First a space-group was assumed, and this assumption was used to generate a listing 
of index positions observing the relevant reflection conditions. A plot of theoretical 
index positions vs. the observed peak positions was then prepared. Plots for the space-
groups Pnn2 and Pba2 are shown later in this section. 
 
b)  After the list of likely space-groups had been narrowed down by visual index position 
matching, the reflection conditions were examined in Excel
® in order to identify 
systematic absences, [60, 61]. Searches were conducted for: 
  General Absences – hkl – indicating a centred lattice 
  Zonal Absences – 0kl, h0l and/or hk0 – indicating the presence of a glide plane(s) 
  Row Absences – h00, 0k0, 00l – indicating the presence of a screw axis(es) 
 
c)  Lastly individual Rietveld refinements of the structural model were conducted for 
each of the shortlisted space-groups. The residual factors resulting from each space-
group trial give numerical output, with which to compare the match to the observed 
data for each assumed space-group. The definitions of the two residual outputs from 
the refinement are provided overleaf, [50, 62]. 
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Equation 11 - Definition of Weighted Profile R-factor, Rwp 






j obs j calc j j
wp









yobs, j = Observed count number at point, j 
ycalc, j = Calculated count number at point, j 
wj = Weighting factor of point, j  
 
The International Tables for Crystallography Volume A list a total of six minimal non-
isomorphic supergroups to space-group 34, Hermann Mauguin symbol Pnn2, suggested by 
Expo. All these alternatives were checked using DRAGON. Among these, one space-group, 
Pnnm shares not only the same index positions; (Appendix 1), but also the same reflection 
conditions. This space-group cannot be discounted solely by using information from the 
powder diffraction data.  
Also checked were the space-groups Pba2 and Pbam. These share identical index positions 
with one another and, between d = 24.4-5.7Å, with space-group Pnn2 also, but their index 
positions diverge slightly from those of space-group Pnn2 at d-spacings below 5.7Å.  
The related space-group Pban fits the data less well; the two small observed peaks at 2θ = 
5.69° and 5.76° are absent from the theoretical index positions. All the quoted 2theta values 
have been rescaled for CuKʱ radiation of wavelength 1.5406Å. 53 




Figure 15 - Phenylbutazone Delta Form in Space-group Pba2 (or Pbam) 
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For the space-groups Pnn2 and Pnnm, which have the same general reflection conditions, the 
fulfilment
11 of general reflection conditions within this limited set of observations is shown in 
the following table. Similarly the fulfilment of general reflection conditions for Pba2 & Pbam 
is shown in Table 7. 
Table 6 - Fulfilment of General Reflection Conditions for Delta in Pnn2 & Pnnm 
Reflection Condition  Condition Observed (Yes/No) 
h00, h = 2n  Yes 
0k0, k = 2n  Yes 
00l, l = 2n  Too few reflections to draw firm conclusion 
0kl, k + l = 2n  Yes 




Table 7 - Fulfilment of General Reflection Conditions for Delta in Pba2 & Pbam 
 
Reflection Condition  Condition Observed (Yes/No) 
h00, h = 2n  Yes 
0k0, k = 2n  Yes 
0kl, k = 2n  Yes 
h0l, h = 2n  Yes 
 
 
These observations indicate that space-groups Pba2 and Pbam are not ruled out. Nonetheless 
the index positions for these space-groups match the observed peaks less convincingly than is 
the case in Pnn2 or in Pnnm. 
                                                           
11 A reflection condition was considered to be met when only the even plane indices indicated were observed; 
this does not necessarily denote that all theoretical even index values could be matched to an observed peak. 
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Refinement of the 6837Å
3 solution was carried out in Expo2004 which has a Rietveld 
procedure built into its structure modelling package. A plausible structural model did not 
emerge, however the R factor of the refinement procedure dropped well below double digits 
for each of the four putative space-groups.  
Refinement residuals for the four space-groups under consideration are displayed in the 
following table. For purposes of comparison the automated Rietveld algorithm was 
employed; this varies a fixed set of refinement parameters.  






Rp & Rwp Values 
Pnnm  Pba2  Pbam 
1  4.63 & 7.19  4.59 & 6.90  5.04 & 10.14  6.15 & 12.15 
2  3.64 & 5.83  3.99 & 6.22  4.35 & 8.94  4.81 & 9.06 
3  3.45 & 5.46  3.87 & 6.04  4.17 & 8.63  4.29 & 8.51 
4  3.29 & 5.18  3.71 & 5.73  3.90 & 8.28  4.13 & 8.41 
5  3.16 & 4.93  3.57 & 5.49  3.50 & 7.92  4.10 & 8.38 
6  3.02 & 4.69  3.34 & 4.83  3.29 & 7.77  4.06 & 8.36 
7  2.95 & 4.60  3.08 & 4.25  3.16 & 7.69  4.05 & 8.34 
8  2.91 & 4.53  2.96 & 4.07  3.10 & 7.65  4.04 & 8.34 
9  2.90 & 4.42  2.88 & 3.96  3.06 & 7.62  4.03 & 8.33 
10  2.68 & 4.25  2.84 & 3.89  3.04 & 7.60  4.03 & 8.33 
Terminal Value  2.47 & 3.93  2.75 & 3.75  2.96 & 7.54  4.03 & 8.33 
 
The terminal output patterns including the residual plots are displayed in the figures overleaf. 
Both the Pba2 and Pbam plots show a large residual at the peak equivalent to a d-spacing of 
5.67Å corresponding to 2θ = 8.36° on the synchrotron diffraction pattern (λ = 0.8269Å) and 
2θ = 15.61° when adjusted to CuKʱ radiation. 
Although the refinement profile residual factor, Rp, is lower for the Pnn2 case, the residual 
plot shows the residual for the largest peaks to be smaller in the Pnnm case.56 
 
Figure 16 - Terminal Residuals from Rietveld Refinements of Delta Form PXRD Pattern 
 
(Y-Axis in counts, X-axis in 2θ, degrees, synchrotron radiation source, λ=0.8269Å. Index positions in red, residuals in purple, diffraction intensity in green) 
 




2Theta (λ = 0.8269Å) 57 
 




2Theta (λ = 0.8269Å) 58 
 
3.2.2  Solvates 
 
Indexing of a number of PXRD patterns of solvates was attempted using data collected on in-
house diffractometers.  The unit cells of the solvates with methyl-tertiary-butylether and 
propylene carbonate were subsequently identified by single crystal diffractometry. 
For the solvates with tetrahydrofuran and cyclohexanone index plots similar to those shown 
for the delta polymorph in the previous section were prepared. Indexing of the solvate with 
cyclopentanone was not attempted, however it is assumed to be effectively identical to the 
solvate with cyclohexanone; (Figure 6). 
 
3.2.2.1  Cyclohexanone Solvate 
 
The indexing results for the cyclohexanone solvate included many monoclinic unit cell 
solutions with a short axis of approximately 6Å and a longer axis of 27Å, therefore 
resembling the solutions of the isostructural solvates with five other solvents identified by 
Hosokawa et al..  
Chekcell’s “best solution” test favoured a monoclinic unit cell with angle ß unique and a 
volume of only 2018Å
3, approximately half that of the isostructural solvates solved by 
Hosokawa et al., and with only the short dimension in common.  
A solution of approximately double the size, 4038Å
3, is also proposed by Crysfire. Both these 
solutions are presented in the following table. In neither case is the software able to identify 
the space-group with high certainty.  
C2/c, the space-group determined for the five isostructural solvates by Hosokawa et al., was 
not favoured by Chekcell’s “truecell” space-group determination algorithm. 
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Monoclinic, ß unique 
Lines Indexed 20, FOM 
16.1 
27.51  5.78  25.71  90  99.09  90  4038 
Monoclinic, ß unique 
Lines Indexed 20 FOM 
8.0 
20.20  5.78  17.29  90  94.07  90  2015
12 
 
3.2.2.2  Tetrahydrofuran Solvate 
 
As mentioned in Section 1.3.2.2, Hosokawa and co-workers have submitted a structure to the 
Cambridge Structural Database for the crystal structure of a solvate of phenylbutazone 
formed with tetrahydrofuran. This solution indicates that the unit cell of the solvate contains a 
total of eight phenylbutazone molecules and four tetrahydrofuran molecules; i.e. the 
API:solvent ratio is 2:1. 
An imputed PXRD pattern is also available on the CSD, which is based upon this SCXRD 
solution. This PXRD pattern does not match the diffraction pattern collected in-house. 
Thermogravimetric analysis was carried out on the solvate produced in-house. Making the 
assumption that the entire recorded weight loss corresponds to the loss of tetrahydrofuran 
bound-up in the crystal lattice of the solvate, an API:solvent ratio of approximately 2:1 was 
present in the in-house sample also. This does not support a hypothesis that there is more than 
one stable solvate structure of phenylbutazone with tetrahydrofuran, possessing different 
solvent:solute ratios.  
                                                           
12 This is Chekcell’s “Best Solution”. Two nearly identical variants were determined – one with 19 lines indexed 
and FOM = 15, the other with 20 lines indexed but with FOM = 8. 60 




As a result of examination of the behaviour of the solvate at different temperatures by in situ 
X-ray diffraction experiments described in Chapter 5, a more plausible explanation for the 
diverging PXRD patterns came to light. The measurement temperature of the SCXRD 
experiments of Hosokawa et al. was 173K. When the in-house solvate was cooled to 150K, a 
different PXRD pattern to the ambient temperature pattern was obtained. Evidently this 
solvate undergoes a structural transition in the temperature range between 150K and 298K. 
While not identical to the calculated PXRD pattern based on the Hosokawa structure on the 
CSD, the in-house 150K pattern does bear a striking resemblance to it; (Figure 18). This 
suggests that the solvate under study is identical in terms of solvent:solute ratio, however that 
the solvate has more than one crystal form. 
                                                           
13 The CIF file indicates that the atom positions of the butyl group of phenylbutazone and the atom positions of 
the tetrahydrofuran molecules are disordered. 
14 Reproduced from Crystal Growth and Design. 61 
Figure 18 - Comparison of THF Solvate Calculated Pattern & 150K Pattern 
 
 
3.3  Structure Determination from PXRD Data 
 
In his 1998 IUCr monograph, [63], Giacovazzo acknowledges the difficulty of conclusive 
space-group identification from PXRD data. He concludes that: 
 “The unequivocal definition of space-group is often difficult from powder data 
even when the unit cell parameters have been correctly defined.”  
He cites the difficulty of identifying systematic absences correctly, because of the presence of 
overlapping peaks, which make it difficult to determine if an absence is actually present. 
Although the use of high-quality synchrotron data makes it possible to identify peak overlaps 
present in PXRD patterns collected on standard X-ray diffractometers, unless a complete 
structural model can be developed, some degree of uncertainty in the assignment of particular 
peaks to calculated index positions is liable to remain.  62 
Achieving a complete structural model of phenylbutazone solely from PXRD data may be 
expected to be a daunting objective. Nonetheless the preponderance of literature and software 
available for the determination of complete crystal structures from powder X-ray diffraction 
data may cause the uninitiated to conclude that PXRD structure solution is almost routine for 
certain classes of molecule.  
Pecharsky and Zavalij, [51], provide a number of examples of inorganic structures that have 
been solved successfully thanks chiefly to the ability to construct models of the structure 
under study from PXRD data alone, and then to refine the atom coordinates using methods 
such as Rietveld refinement. The ability of programs such as Mercury, [64], and Powdercell, 
[65], to calculate an imputed powder pattern from a completed molecular structure enables 
the integrity of a finished structural model to be confirmed independently.  
However other crystallographers are notably more sanguine about the obstacles involved in 
achieving a complete structural solution from powder diffraction data, particularly for organic 
molecules above a certain size and complexity. Werner, [53], puts it this way:  
“In principle, all information available in a single-crystal diffraction pattern is 
also available in a powder diffraction pattern. Suppose all the pages in a book 
have been printed on top of each other on one single sheet. Obviously everything 
written in the book is present on the paper, but this does not mean that we are 
able to extract the information.” 
A recent list of structure solutions of a variety of molecular structures that have been arrived 
at from PXRD data is provided in a paper from the Istituto di Cristallografia, which is 
included in the same 2002 IUCr monograph on PXRD structure determination methods, [66].  63 
Several software packages, including Expo, provide Cimetidine, C10H16N6S, as an example of 
a small organic molecule whose structure is soluble from its powder diffraction pattern.  
Despite the availability of high quality synchrotron powder diffraction patterns efforts to 
solve the structure of the alpha and delta forms of phenylbutazone using Expo, Fox and the 
Superflip procedure in Jana2004, were not successful, [67, 68]. Phenylbutazone, C19H20N2O2 
is considered too large to be solved by the reverse Monte Carlo and “pseudo” simulated 
annealing algorithms contained in the program, Espoir.  
In consequence, structure solution of solvates of phenylbutazone from PXRD data was not 
attempted. The subsequent sections concern structure solution from single crystal X-ray 
diffraction data, SCXRD. 64 
3.4  Collection of Single Crystal Diffraction Data 
3.4.1  Growing Suitable Crystals 
 
The first step in structure determination by single crystal diffraction is the growth of suitable 
crystals. Mentions of the challenges involved in growing crystals of adequate quality for this 
purpose are not hard to find, [61, 69, 70].  
Unless special care was taken, 
the crystallization of 
phenylbutazone generally 
resulted in samples unsuitable 
for single crystal diffractometry. 
 The alpha and delta form 
specimens shown to the left are 
the results of routine evaporative 
crystallization in a single 
solvent. The beta form sample 
was precipitated from warm 
methanol using water. 
Figure 19 - Phenylbutazone Polymorph Specimens 
 
For only one polymorph, the alpha form, was it possible to grow “macro” crystals that were 
translucent in polarized light in all but one orientation, in which no polarized light could pass 
through; an effect often referred to as extinguishing of the polarized light, [71]. 65 
 
 




Figure 21 – Alpha Form Crystal Selection for SCXRD 
 
 
Although many of these large crystals 
displayed visible imperfections; e.g. air-
bubbles, it was possible to locate 
specimens, from which adequate quality 
sections could be cut. 
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The standard route to the beta polymorph, precipitation from organic solution using water, is 
not conducive to the formation of large, single crystals; particularly when the solution is 
stirred. Formation of pure beta form was found to have occurred at the edge of a watch glass 
from which a highly volatile solvent had rapidly evaporated, resulting in the emergence of 
side-blooms. Regrettably these consisted of congealed, powdery deposits, inherently 
unsuitable for single crystal diffraction experiments. Kaneniwa et al., [71], provide pictures 
of large, rod-shaped crystals of the beta form, which they were able to grow in ethanol 
solution. During this investigation, numerous crystallizations of phenylbutazone in methanol 
and ethanol failed to yield a similar result. 
The typical crystal habit of the delta polymorph is a fibrous matrix of varying hardness, 
whose constituent strands rarely extend to a width of even 50 µm. While these crystals yield a 
highly reproducible powder X-ray diffraction pattern, none has shown promise for single-
crystal X-ray diffraction experiments. 
Figure 22 - Alpha Single Crystal after Heating 
 
The ability to produce the delta form 
by heating of the alpha polymorph of 
phenylbutazone gave grounds for 
optimism about obtaining a delta 
crystal suitable for SCXRD via heat-
treatment of the alpha form. 
Unfortunately this technique leads to 
the formation of imperfect crystals 
such as the one shown opposite.  67 
 
High quality single crystals of solvates were prepared from methyl-tertiary-butylether, 
propylene carbonate and cyclohexanone. By contrast attempts to grow single crystals of the 
solvates with tetrahydrofuran and cyclopentanone did not yield “macro” crystals.  
The pictures shown in Figure 23 were taken using the camera installed on the single crystal 
diffractometer. The crystal is adhered to a cylindrical glass fibre mount by means of a small 
amount of an X-ray neutral, encapsulating oil, which also serves to prevent solvent escape 
from solvated crystals. 
Figure 23 - Single Crystals that Yielded Structure Solutions on the SCXRD Goniometer  
Methyl-tertiary-butylether Solvate   
 
Propylene Carbonate Solvate 
 68 
3.5  Structure Determination from Single Crystal Diffraction Data 
 
Full SCXRD datasets were typically 
collected only in those cases where a 
plausible unit cell could be determined in the 
preliminary collection of the orientation 
matrix. The pre-screening of crystal 
specimens both by visual appearance under 
the microscope and according to the 
plausibility of the unit cell options 
determined during collection of the 
orientation matrix, helped keep the number 
of insoluble datasets in check.  
Figure 24 - Checklist for Structure Solution 
a) Dataset Coherence 
The presence of twinned crystal specimens was mooted as a cause of data processing 
difficulties in certain instances. Investigation of the datasets in question using the Bruker 
Gemini software program, designed to enable the processing of datasets from twinned crystal 
samples, part of the Shelxtl suite, did not lead to confirmation of this diagnosis, however. On 
only one occasion was it possible to identify a pattern in the raw dataset that pointed 
conclusively to a major crystal fault; a grouping of high reflection intensities along a 
particular h,k,l index, which became apparent during manual inspection of the raw reflection 
file. This anomaly was subsequently confirmed by the structure solution software packages, 
SIR, [72]  and Jana, [73], with which the dataset in question was processed in parallel to the 
manufacturer-supplied software.  
a)  Coherent Dataset? 
 
b)  Symmetry Detected? 
 
c)  Plausible Structure Model? 
 
d)  Can Structure Be Assembled? 
 
e)  Is Structure Valid  





b) Symmetry Detection 
A more frequent occurrence was a failure to determine any symmetry above triclinic, even 
when data from a specimen believed to have a monoclinic lattice were being analysed; e.g. 
the alpha form of phenylbutazone. Although an adequate .hkl file could be generated and 
processed to yield an electron density map, this did not result in a set of atomic positions with 
features of phenylbutazone’s molecular structure discernible in the subsequent 3-dimensional 
model; e.g. planar phenyl groups. 
 
c) Structure Model Plausibility 
Typically the detection of a plausible space-group was the prelude to generation of a model, 
in which certain aspects of the anticipated structure could be recognized. For example, during 
the solution of structures of a number of solvates of phenylbutazone, the symmetry search 
yielded a space-group that had been determined for other phenylbutazone solvates, and the 
location of the drug molecule was readily distinguishable from the electron density map. 
 
d) Structure Assembly 
The manner of structure assembly varies widely among different single crystal structure 
solution software packages. While this step is carried out manually in Shelxtl and in Jana, 
SIR2004 is capable of recognizing likely bond positions, and proved particularly adept at 
finding the location of phenylbutazone molecules more or less in their entirety, identifying all 
the ring moieties automatically. In all the solvated structures locating the solvent molecules 
proved challenging regardless of the software employed, and taxed the ability of the graphical 
user interfaces to situate consistent molecular forms. 
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e) Structure Validation & Refinement 
Having arrived at a plausible structural model, it remains to validate and refine the findings. 
In the case of determination of previously solved structures such as the alpha form of 
phenylbutazone, the model was validated by comparison with prior solutions. Prior solvate 
structure solutions are also available for comparison. In common with the PXRD datasets, 
raw files of reflections could be analysed in Excel
® in order to confirm individual extinction 
conditions.  
For example, during data reduction by Shelxtl, the space-group of the alpha form was 
identified as monoclinic with space-group number 14 and Hermann-Mauguin symbol, P21/c. 
The International Tables for Crystallography, Volume A, point out that various different 
forms of this space-group exist depending on choices of origin and unique axis. The dataset 
collected does not display reflection condition, h00: h=2n, but instead fulfils conditions: 
  00l: l = 2n 
  0k0: k = 2n 
  h0l: l = 2n 
This allows the space-group selection to be narrowed down to unique axis b, cell choice 1, 
which has the more precise space-group symbol of P121/c1. 
 
3.5.1  Refinement of SCXRD Solutions – Theoretical Background 
 
The objective of the refinement of single crystal structure solutions is to improve upon the 
initial structure “solution” of calculated electron densities derived from measured intensities 
and estimated phases. These phase angles are calculated numerically (e.g. by direct methods) 
in order to make up for the absence of experimental phase information to accompany 71 
intensity magnitudes measured at the detector; phase information that is subsequently 
required in Fourier synthesis of electron densities as can be seen in the three dimensional 
expression for electron density, ρ, shown below. The electron density values are used to 
construct a map such as the 2-dimensional example shown in Figure 25: 
 
Equation 12 - Expression for Calculation of Electron Density in Real Space 
 
   
1
cos 2 ( ) hkl hkl
h k l c
xyz F hx ky lz
V
         
Where: 
x, y, z = Unit cell coordinates 
Vc = Volume of the unit cell 
Fhkl = Observed structure amplitude for reflection plane, h,k,l 
h,k,l = Plane indices 
φhkl = Phase angle of diffraction vector for reflection, h,k,l 
 
Figure 25 - Example Section of 2D Fourier Map of Alpha Form created in Jana2004 
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Information about the phase angle is not provided at the X-ray detector, and phase values 
must be deduced in order to solve the crystal structure. This circularity is the essence of the 
so-called, “phase problem”. The use of “Direct Methods” is among the most common 
techniques to solve the structure of organic molecules, and was employed extensively during 
this study, [63].  
From the electron density values, form factors are also determined. The expression for 
calculation of form factors for each atom, fi, (alternatively termed atomic scattering factors), 
closely resembles the expression for the atomic Debye-Waller factor, (Equation 17), and is 
outlined by Shmueli and Massa among others, [61, 74]. Values of form factors for different 
elements are tabulated in the International Tables for Crystallography Volume C, [75]. 
 
Structure factors, Fc, which sum the estimated contribution of each atom in the unit cell in 
scattering the X-ray beam to arrive at a theoretical intensity value for each reflection plane, 
may then be calculated using the expression shown below: 
Equation 13 - Expression for Calculation of Structure Factor, Fc 
      F cos2 sin2 c i i i i i i i
i
f hx ky lz i hx ky lz          
The observed structure amplitudes, Fo, are typically obtained from the measured diffraction 
intensity, I, according to the following expression, in which the denominator term 
corresponds to the Lorentz Polarization correction:  












                                                           
15 An absorption correction is typically applied to the raw intensities also 73 
Differences between the observed structure amplitude, Fo, and calculated structure factors, 
Fc, result from errors in both the model and the data. The first step in refinement packages for 
SCXRD data is typically a least squares algorithm that minimizes the sum of the differences 
between the values of Fo and Fc. Certain refinement packages, such as CRYSTALS, [76], 
permit refinement, not only of the squared Fo values, but also their moduli, an important 
option, particularly where data intensity is weak. The expressions for calculation of the 
commonly encountered least squares residual factors are shown below: 
Equation 15 - Refinement Residual, R of Modulus F Values 











































The quantity, w, refers to the weighting factor applied to the individual measurement point. 
This is intended to take into account the fact that, in proportional terms, the measurement 
errors are larger for weak intensity readings than for strong ones. In the simplest case, a 
weighting factor of 
2 1 w   is often employed, where ζ is the standard deviation in the 
measured data; (Appendix 5). 
For refined structures, the value of the residual, R, typically lies in the range of 0.05-0.15. 74 
Only after least squares refinement, and achievement of a reasonable R value, do most 
refinement packages draw the user’s attention to the atomic displacement of individual atoms 
in the structure. These are intended to account for the fact that atoms are not stationary, and 
that the measured electron densities at each atomic location in fact represent average values. 
Variations in atomic position are shown to decrease, as the measurement temperature is 
lowered, and result from: 
  external displacement of the molecule as a whole, and   
  internal, interatomic bond displacements.  
Generally the latter have a much smaller effect than the former. Disorder in the structure 
may also be apparent, and is typically subdivided into two varieties: 
  Positional disorder - this occurs when an atom or group of atoms (perhaps making 
up an entire molecule such as an incorporated solvent) is/are statistically distributed 
over two or more positions. 
  Orientational disorder - this connotes that a molecule is distributed over two 
orientations, usually related by a symmetry operation; e.g. rotation or inversion. 
 
The treatment of atomic displacement is integral to the solution of the phase problem and the 
calculation of meaningful unitary structure factors. An overview of this topic is provided by 
Shmueli among others, and a harmonized, mathematical treatment of atomic displacement is 
set out in a publication of the IUCr, [74, 77]. In the development of the atomic Debye-Waller 
factor, (also known as the “atomic temperature factor”), these texts distinguish between: 
  Isotropic displacement - uniform displacement in all directions, and  
  Anisotropic displacement - directionally specific displacement 75 
 
In the former case, a spherically uniform mean squared displacement is assumed for all 
atoms. By contrast, in the latter case, a Gaussian distribution is usually assumed, and the 
electron density values are distributed in the direction of the diffraction vector, k, giving rise 
to an ellipsoid. These “thermal ellipsoids” are unique to each atom in the structure: 
Equation 17 - Anisotropic Debye-Waller Factor, T 
 












   
Where: 
uk = Atomic displacement of diffraction vector, k 
λ = Wavelength of radiation source 
θ = Diffraction angle 
 
The quantity sin  is familiar from the Bragg equation as being equal to a distance from 
the origin in reciprocal space, d*; (more precisely ½n.d*). It is used, not only in calculations 
and plots of atomic displacement caused by thermal vibration, but also, in compilations of 
intensity statistics for SCXRD datasets, in which the several thousand individual reflections 
are typically subdivided into a series of concentric shells with the origin of the reciprocal 
lattice at its centre. 
The length of the smallest reciprocal d-spacing that can be resolved in an experiment is given 
by the distance from the edge of the Ewald sphere to its centre, a fixed value of 1/λ.  Shelx, 
[78], presents the intensity data for each shell spacing using the term resolution to refer to the 
valuesin . 76 
Figure 26 - Visualization of the Ewald Sphere
16 
 
In the example of the Bruker SCXRD dataset of the alpha polymorph of phenylbutazone (Mo 
Kʱ radiation, λ = 0.7107Å) shown below, the reflection listing indicates the range of 2theta 
across which measurement was made, as well as the corresponding “resolution”. It is 
apparent from this calculation that much higher resolution is achieved at higher diffraction 
angles, an effect alluded to by Shmueli. 
Table 10 - Phenylbutazone Alpha SCXRD Measurement Resolution 
 
  2θ(ﾰ)  Resolution (Å) 
Minimum  5.721  7.121 
Maximum  54.690  0.774 
                                                           
16 Reproduced from Pecharsky & Zavalij, Fundamentals of Powder Diffraction, 2005, Springer, New York,  p151. 
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3.5.2  Summary of SCXRD Structure Refinements 
 
The unit cell dimensions of phenylbutazone alpha form are shown in Section 3.2.1.1. No 
SCXRD solution was achieved for either the delta or the beta polymorphs owing to the 
absence of suitable single crystals. 
Using SCXRD complete structure solutions were achieved for two of the four new solvates 
discovered during this investigation, and their unit cells dimensions are shown in the 
following table: 



























(±0.006)  90  96.835 









(±0.001)  90  92.990 
(±0.030)  90  3660.01 
 
Refinement of the raw structures to single digit residuals proved to be difficult for the solvate 
structure solutions, in particular; these both contain ambiguous solvent atom positions. 
Efforts at manual refinement of Bruker Shelxtl .RES files using the academic version of 
Shelx were problematic, owing, not least, to syntax compatibility problems.  
Using the refinement capabilities of CRYSTALS it was possible to lower the residual 
significantly simply by conventional least squares refinement. The special features in this 
package, most notably the ability to alter the selection of the intensity cut-off parameter, 
I/Sigma(I), aided in lowering the residual for the alpha form solution into high single digits, 
                                                           
17 Unit Cell Parameters changed slightly during refinement. 78 
but only by sacrificing many of the reflections of which the model is comprised; sometimes 
to a total of below 1000 reflections.  
Refinement against F and F
2 was carried out; little or no improvement in R value was 
observed after switching to F
2 refinement, and the weighted R values increased substantially. 
Results of refinement against F are therefore reported.  
The value of the Goodness of Fit, GoF, gives an indication of how well the structural model 
fits the data. Values close to unity are considered ideal, while a value of below unity indicates 
that the model is better than the data, a situation referred to as “overfitting” of the model. 
 
Adjusting the weighting factor, w, is a further technique that can be carried out in 
CRYSTALS in order to attempt to improve the GoF value, whose method of calculation is 
shown below: 
 



















w = Weighting factor 
Fo = Observed structure amplitude 
Fc = Calculated structure factor 
NR = Number of independent reflections 
NP = Number of refined parameters 
 
An overview of the refinement statistics for the three structure solutions of phenylbutazone 
polymorphs and solvates achieved during this investigation is shown in the following table:  
 79 
Table 12 - Refinement Statistics of Solved Phenylbutazone Structures 
 
  R  wR  GoF  Fo/Fc  I/Sigma(I)  No. of 
Reflections 
Alpha polymorph 
  8.149  5.678  1.191  1.242  7.0  1273 
Methyl-t-butylether 
solvate  10.540  12.514  0.949  1.047  3.0  1500 
Propylene Carbonate 
solvate  16.968  19.039  1.820  1.042  3.0  1761 
 
Plots of residual factor, R, vs. sin  (½n.d*), are shown in the following figures for each of 
the three structure solutions:80 















3.6  Structural Models 
3.6.1  Alpha Polymorph 
 
Singh and Vijayan show a truncated alkyl tail on one of the two phenylbutazone molecules in 
the asymmetric unit of their alpha form structure, which is available on the CSD: 
Figure 30 - Alpha Form Asymmetric Unit - Singh & Vijayan, 1978 
 
The in-house structure exhibits one molecule with a well-formed alkyl chain, the other 
contains less uniform alkyl-group bond distances and angles. A number of CIF files of 
solvate structures deposited into the CSD indicate disorder in this part of phenylbutazone’s 
structure also.  
In an effort to improve the refinement values of the alpha form structure solution, removal of 
poorly defined atoms was undertaken. The refinement procedure was then repeated, however 
little or no improvement in residual values was observed.  
The following figures display the asymmetric unit and unit cell of the in-house alpha form 
solution. The oversize thermal ellipsoids from anisotropic refinement displayed in the 
foremost C4 chain of the asymmetric unit are an indicator of ill-defined atomic positions.84 








As a further crosscheck of the refinement results, an imputed powder pattern was obtained 
from the refined .CIF file using Mercury. The calculated and observed peak positions display 
a good match to each other. 
 
Figure 33 - Comparison of Calculated & Observed PXRD Patterns of Alpha Form 
 
 
3.6.2  Propylene Carbonate & Methyl-tert.-butylether Solvates 
 
The structures of the solvates with propylene carbonate and methyl-tertiary-butylether posed 
a different difficulty. In neither case were the solvent molecule positions clearly defined. 
After initial least squares refinement, the atomic positions of the phenylbutazone molecule 
were readily discernible, and displayed a well-ordered C4 tail. However the various 
remaining pockets of electron density did not provide unambiguous sets of atom positions for 
the solvent molecule.  
 86 





From the standpoint of structure assembly, SIRWARE was the most adept at enabling 
plausible solvent structures to be completed. By contrast only partial assembly was possible 
in CRYSTALS, owing to constraints imposed by the software.  
Although SIRWARE allowed more flexible atom positioning, upon carrying out least squares 
refinement on the solvate structure, attention was quickly drawn to the fact that imposed 
solvent atom positions did not correspond closely to areas of electron density in the 
underlying Fourier map; an obstacle that the software overcame by attaching large thermal 
parameters to those atoms. Disorder is also apparent in the positions of the solvent molecules, 
which is apparent from the additional solvent atom positions depicted. 
The completed structural models of the two solvates are displayed in the following figures: 
                                                           
18 Viewed normal to unit cell axis b. 87 




Figure 36 - Unit Cell of Methyl-tertiary-butylether Solvate 
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Figure 38 - Unit Cell of Propylene Carbonate Solvate 
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For these two solvate structures, comparison of the observed PXRD patterns and the imputed 
patterns calculated from the SCXRD-derived structure models reveals a number of 
discrepancies. For the solvate with methyl-tertiary-butylether: 
  The first two peaks in the observed pattern overlap – preferred orientation is a 
possible cause. Repeat PXRD experiments led to the same peak shape, however. 
  A 2theta offset is apparent, which may be attributed to the difference in measurement 
temperature. 
  The peak at 2θ = 8.3ﾰ in the observed patterns is absent from the calculated pattern. 
 





The discrepancies in the observed and calculated PXRD patterns of the propylene carbonate 
solvate at low 2theta are less easily attributable to the difference in measurement temperature. 
Clearer correspondence between the two patterns is observed at higher angles. 
 




The isostructurality of these and five other phenylbutazone solvates examined previously 
suggests that phenylbutazone forms an assembly that is, at least to some extent, structurally 
independent of the solvent molecule. However the differences in unit cell volume indicate 
that the solvent molecule is influencing the configuration of this assembly.  
A comparison between the different solvates with space-group C2/c is provided in the 
following table:91 
 
Table 13 - Overview of 7 Isostructural Solvates of Phenylbutazone 
 







 Chemical Formula  C6H6  C6H12  C4H8O2  C4H8O  CCl4  C5H12O  C4H6O3 
 Molecular Weight  78.1  84.2  88.1  72.1  153.8  88.2  102.1 
 
SOLVATE 
             














Molecular Weight  347.5  350.5  352.5  344.5  385.3  352.5  359.5 
 
SOLVATE UNIT CELL 
             
Research Group†  1  1  1  1  1  2  2 
Crystal System  Monoclinic  Monoclinic  Monoclinic  Monoclinic  Monoclinic  Monoclinic  Monoclinic 
Space-group  C2/c  C2/c  C2/c  C2/c  C2/c  C2/c  C2/c 
Z  8  8  8  8  8  8  8 
a  22.407  25.653  22.567  22.614  25.263  25.708  22.433 
b  6.061  5.609  6.002  5.981  5.646  5.647  5.993 
c  27.148  27.551  27.224  27.193  27.459  27.610  27.261 
beta  91.107  98.621  93.444  93.819  99.117  96.835  92.990 
Volume  3686.2  3919.5  3680.5  3669.9  3866.8  3974.7  3660.0 
Calculated Density  1.25  1.19  1.27  1.25  1.32  1.18  1.31 
REFINEMENT               
Reflections  3264  3479  3259  3237  3419  3662*  3103* 
R1  0.0651  0.0567  0.0425  0.059  0.0452  0.1054  0.1679 
wR2  0.1491  0.1347  0.1022  0.1309  0.1003  0.1251  0.1899 
 
*After merging of Friedel opposites, but before final refinement. 
† 1 = Hosokawa et al., 2004; 2 = Targett & Cockcroft, 2008. 92 
 
4  Polymorphic Outcome of Solvent Crystallization 
 
The importance of being able to predict and control the polymorphic form or forms that a 
molecule adopts upon crystallization was outlined in the introductory section. Although an 
exhaustive examination of the causes of polymorphic crystallization outcomes is undoubtedly 
worthy of an entire investigation in its own right, the most salient factors are introduced in 
this section. Particular attention is paid to the solubility behaviour of individual polymorphs, 
which forms the basis of the simplest model for the prediction of polymorphic outcomes of 
solvent crystallizations, the preferential solubility model. 
 
4.1  Preferential Solubility Model 
 
This model is analogous to the 
methodology used to predict how 
mixtures of two or more solutes with 
different solubility profiles will 
crystallize out of solution during 
solvent crystallization. In this 
important industrial technique, the 
temperature of a supersaturated liquor 
is adjusted to control the rate of 
crystallization of a target solute, [79].  
 

















It is straightforward to conceptualize the formation of a particular polymorph in terms of 
preferential solubility also. The graph depicts saturation concentrations of a pair of 
polymorphs, A & B, over a given temperature range. Moving from right to left along the 
line of constant concentration represented by the horizontal bar, once the temperature falls 
below the intersection with the blue saturation curve for the less soluble polymorph A, the 
solution is supersaturated with respect to this polymorph, and it can be expected to 
crystallize out of solution. As long as the temperature remains above the intersection with 
the pink saturation curve for polymorph B, no polymorph B is expected to crystallize.
It should be borne in mind, that below high saturation conditions, the dissolved solute 
molecules cannot be considered to possess even short range order, and should not be regarded 
as a mixture of distinct polymorphs, but rather as a collection of disordered solute molecules 
in solution. In the case of molecules such as phenylbutazone, this situation is complicated 
somewhat by the difference in the rate at which different polymorphs dissolve. There are also 
substance-specific factors to be considered, such as the influence of crystal habit and particle 
size on the rate of dissolution. 
The crystallization behaviour of several molecules that exhibit polymorphism has been 
investigated by Kitamura et al., [80-84], with a view to understanding the determining factors 
of the resulting polymorphic composition. The crystallization of glutamic acid has also been 
the subject of a recent in situ synchrotron study performed by a team that included 
researchers at the University of London, [85]. The study was completed within the 
framework of a research programme, based at the University of Leeds, entitled “Chemicals 
Behaving Badly”. Using a specially-designed, stirred crystallization apparatus in combination 
with an intense synchrotron beam, it has proved possible to discern the formation of bands of 
polymorphs in crystallization mixtures of glutamic acid.  94 
4.2  Dissolution 
In order to understand how valid the preferential solubility model is in determining 
polymorphic outcomes, it is first helpful to consider the dissolution behaviour of the solute. 
In the case of materials that exhibit polymorphism it was stated earlier that differences in the 
rate of dissolution between different polymorphs of the same molecule are regularly 
encountered. Solubility behaviour is of relevance in all steps of the usage chain in many 
industries, including pharmaceuticals, where it has bearing during: 
  synthesis and crystallization of the active ingredient 
  preparation of the dosage form; e.g. tablet production 
  behaviour of the pharmaceutical ingredient in vivo 
Pharmaceutical active ingredients elicit particular attention not least, because they are, in very 
many cases, insoluble in water, and therefore require modification and/or formulation in 
order that they may have the desired therapeutic effect. Yang et al.,[7], identify the entire 
class of API to which phenylbutazone belongs, non-steroidal anti-inflammatory drugs, as 
having very low aqueous solubilities. 
 
4.2.1  Ideal Solution Theory 
 
The thermodynamic treatment of the dissolution of solids considers the idealized effects of 
the forming and breaking of intermolecular bonds. For an ideal solution, comparison is drawn 
between the bond breaking process that occurs during dissolution of a solid and that which 
occurs during transition of the solid to the liquid phase at the melting temperature
19.  
                                                           
19 Constant pressure is generally assumed. 95 
Frequently, however, dissolution is accompanied by additional, non-reactive bonding 
processes, which are typically exothermic; for instance the formation of hydrogen bonds or 
the creation of micelles. A commonly observed consequence of “mixing” bonding is the 
temperature rise upon mixing of two liquids
20, commonly referred to as the heat of mixing.  
For dissolution of a solid in a solvent under ambient conditions, the heat of dissolution may 
be considered to be the sum of the heat of melting, usually an endothermic process, and the 
heat of mixing, usually an exothermic process: 
Equation 19 - Enthalpy of Solution of a Solid Solute 
 
  solution mixing fusion H H H      
In the situations under consideration, the dissolution process occurs below the solute’s 
melting temperature, and an adjustment for the enthalpy terms is introduced in order to take 
into account the difference between the temperature at which the melting enthalpy has been 
measured and the temperature at which the dissolution process is taking place. For the heat of 
fusion this adjustment is calculated using the following integral, whose form is also valid for 
the enthalpy of mixing:  








H H C dT    
Where: 
T H = Enthalpy of solute at measurement temperature 
Fusion T H  = Enthalpy of solute at melting temperature 
                                                           
20 Two liquids (or solutions) at the same starting temperature. 96 
Tfusion = Temperature of fusion 
T = Temperature of measurement 
Cp = Heat capacity at constant pressure 
 
Typically it is assumed either that the heat capacity is constant over the temperature range in 
question, or that its variation is linear. Where the heat capacity is constant, the integral above 
simplifies to ()
Fusion T T p Fusion H H C T T    . Often this correction is small, and frequently it is 
neglected altogether. The definition of an ideal solution includes the assumption of complete 
dissociation by a given solute in all solvents, and the absence of a heat of mixing.  
In ideal solution theory all individual characteristics of the solute are ignored; for example, 
the type of bonding present in the solute; ionic, covalent, containing a dipole, etc. Although a 
simplification, this approach serves as a basis for derivation of useful thermodynamic 
proportionalities for the bulk solution, which are readily observable; most notably the inverse 
relationship of the temperature of the solution to logarithmic solute concentration, which is 
captured in the van’t Hoff relationship: 
Equation 21 - The van't Hoff Equation 
 









[xsolute] = Mole fraction of the solute 
ΔHfusion = Heat of fusion of the solute  
ΔSfusion = Entropy of fusion of the solute 
R = The gas constant 
T = Absolute temperature 97 
This expression is derived from the free energy change of mixing, which may also be 
calculated from the mole fraction of concentration according to: 
Equation 22 - Free Energy Change upon Mixing 
 
  ln solute G RT x   
Rearranging this expression gives: 






For the ideal case, the enthalpy of mixing is equal to zero, and from Equation 19: 
solution fusion HH     
Remembering the Helmholtz relationship; commonly expressed as follows: 
Equation 23 - General Form of the Helmholtz Equation
21 
 
  H G TS   
Where: 
H = Enthalpy 
G = Gibbs free energy 
T = Temperature 
S = Entropy 
 
The change in free energy upon dissolution may be expressed in terms of heats of fusion as 
follows: 
dissolution fusion fusion G H T S       
                                                           
21 The Helmholtz free energy, A, is related to the Gibbs free energy, G, by the equality  G A P V     , 
where P and V refer to pressure and volume respectively. In processes where no expansion or contraction 
occurs ∆V = 0, and the Gibbs & Helmholtz free energies may be considered equivalent. 98 









At the melting temperature, the free energies of the two states are assumed to be equal. This 
assumption is also made with respect to transitions between polymorphs, which are discussed 
in Section 5.1. This assumption allows the entropy of fusion to be calculated as follows: 
Equation 24 - Entropy of Fusion at the Melting Temperature 
   































This is the most commonly encountered form of the van’t Hoff equation. The ideal solubility 
equation is derived from it. Kirchoff adjustments; (Equation 20) are applied, in order to 
account for the fact that: 
i.  the solution is at a lower temperature than the melting temperature of the solute. 
ii.  the heat capacity at constant pressure may vary over the temperature range under 
examination. 99 
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ΔCp is the difference in the heat capacity of the solute between the melting temperature and 
the measurement temperature. Not infrequently the Kirchoff correction terms are omitted. 
The derivation is discussed further by Streng, [33]. 
 
4.2.2   Non-Ideal Solution Theory 
 
As discussed in the previous section, the ideal solution is a largely conceptual entity. Ionic 
solutions conform most closely to its precepts. The most widely encountered theoretical 
method to predict the solubility of non-electrolytes was developed by J.H. Hildebrand, whose 
thermodynamic treatment is referred to as “regular solution theory”; [30, 31, 33, 86, 87].  
A regular solution is defined as, “one involving no entropy change when a small amount of 
one of its components is transferred to it from an ideal solution of the same composition, the 
total volume remaining the same.”  
Streng paraphrases thus: “a regular solution can have a non-ideal enthalpy of formation but 
must have an ideal entropy of formation”. 
In prelude to a discussion of regular solutions it is typical to introduce the property of a solute 
known as its activity, a measure of the deviation of that solute from ideal behaviour: 
Equation 26 - Definition of the Activity of a Solute 
 
    xx ax    100 
Where: 
ax = Activity of solute, x 
[x] = Molar concentration of solute, x 
γx = Activity coefficient of solute, x 
 
The activity may be used in place of the concentration term in many thermodynamic 
expressions, in order to achieve a closer fit to measured data.  
Regular solution theory considers non-ideal aspects of the solution such as its enthalpy of 
mixing, and defines an independent solubility parameter for each solute and solvent 
component on the basis of its heat of vapourisation and molar volume
22: 











ʴx = Solubility parameter of component, x 
x vap H  = Enthalpy of vapourisation of component, x 
Vx = Molar volume of component, x 
 
These parameters are considered characteristic of a given molecule, and may be used for that 
substance in any given combination of solvent(s) and solute(s), in which the substance is 
included.  
Regular solution theory expressly provides for solutions of multiple solvents and solutes. 
This convenience factor has wide attraction, particularly in situations where mixtures of large 
numbers of solvents are commonplace; e.g. hydrocarbon processing.  
                                                           







  101 
For a solution comprising a single solvent and a single solute, the activity of the solute is 
related to the Hildebrand solubility parameter as follows: 
Equation 28 - Activity of Solute in terms of Hildebrand Solubility Parameters 
 
   
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VSolute = Molar volume of the solute 
ʦSolvent = Volume fraction solvent 
ʴSolvent = Solubility parameter of the solvent 
ʴSolute = Solubility parameter of the solute 
R = The gas constant 
T = Temperature of measurement 
 
From the definition of the activity coefficient: 
    ln ln ln solute solute solute xa      
Combining the van’t Hoff equation with the expression for the activity coefficient yields: 
 
Equation 29 - Hildebrand Solubility Equation 
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The Hildebrand solubility term is assumed to correct for the non-ideality of the solution, and 
the solute’s activity term is therefore replaced by its concentration. Its value must always be 
positive; i.e. it lowers the value of solute concentration; (Figure 43).  102 
Solubility parameters for commonly used solvents are widely available, and have been 
compiled in a handbook, [88].  By contrast values of solubility parameters and molar volumes 
have only been measured for a relatively small proportion of APIs. 
For many organic molecules, including APIs, the definition of the solubility parameter in 
terms of heats of vapourisation is only of indirect relevance; many of these substances tend to 
undergo irreversible decomposition before boiling. Proponents of the Hildebrand approach 
state that it is necessary to consider a hypothetical sub-cooled liquid reference state in order 
to obtain solubility parameters for solutes that are solid at room temperature; the solute’s 
solubility parameter may then be calculated from the solid’s heat of sublimation. In many 
instances the solute’s tendency to sublime is, however, minimal.  
Various different methods have been devised to evaluate the solubility parameters of solutes 
experimentally, and they are often referred to as “cohesion” parameters, [29, 88, 89]. Streng 
employs heats of mixing in his derivation of solubility parameter values for solutes.  
As well as the inherent solubility of a particular solute in a solvent or a mixture of solvents, a 
range of kinetic factors also play an important role in determining the rate at which 
dissolution occurs. These factors include: 
  the size of individual solute particles 
  their wetting characteristics in a particular solvent or blend 
  mixing conditions; e.g. agitation and/or stirring 
Among the methods commonly used to capture the effects of these factors are the Ostwald-
Freundlich equation, (also known as the Gibbs-Thomson equation), and the Noyes-Whitney 
equation, [79, 90]. 103 
4.2.3  Solubility of Phenylbutazone 
 
Based upon the melting points and heats of fusion reported by Kaneniwa et al.; (Table 18), 
the ideal saturation solubility of phenylbutazone was calculated using the ideal solubility 
equation, (Equation 25), in its simplified form, which excludes measurement temperature 
adjustments. The heat of fusion of the different polymorphs increases in the order; beta, delta, 
alpha. A plot of ideal solubility against temperature is shown in the figure below. 
 
Figure 42 - Ideal Solubility of Phenylbutazone Polymorphs vs. Temperature 
 
 
This method may be used to obtain the solubility for phenylbutazone in any solvent, simply 
by altering the molecular weight of the solvent, upon conversion from molar to mass units. 
The solubility ratios of the polymorphs calculated in this manner are in agreement with the 
range of 1.0-1.3 reported by Pudipeddi et al., [91]. 104 
As stated earlier, this technique does not take into account specific solvent incompatibilities; 
for example phenylbutazone’s insolubility in water. A better fit to observed data is to be 
expected from the modified van’t Hoff equation incorporating Hildebrandt solubility 
parameters; (Equation 29). Insolubility of phenylbutazone in water, (solubility parameter ~ 
48 MPa
½), is correctly predicted by regular solution theory.  
The solubility parameter of phenylbutazone was reported by Rey-Mermet et al., [29], without 
reference to the polymorphic form, but calculated using a range of different techniques, 
including induction from actual solubility measurements. Most routes indicate a solubility 
parameter in the region of 23-30 MPa
½, but Rey-Mermet et al. point out that the value 
calculated from actual solubility measurements in methanol implies a solubility parameter of 
only 16.8 MPa
½.  The solubility of phenylbutazone (at ʴ = 25 MPa
½) in a selection of 
solvents, according to ideal and regular solution theory, is shown in the figure below. 
Figure 43 - Ideal and Non-Ideal Solubilities of Phenylbutazone
23 
 
                                                           
23 Thermal data for the delta form were used in these computations. 105 
Quantitative solubility measurements were not conducted during this investigation. Solubility 
values in three organic solvents, including acetone, are provided by Datta and Grant, [92]. 
Several literature measurements of solubility in aqueous buffer solution indicate an 
equilibrium saturation concentration for the alpha, delta and beta polymorphs in the region of 
1.0–1.5 mg/ml at room temperature.  
The following figure shows solubilities of individual polymorphs over a range of 
temperatures, measured in a phosphate buffer solution of pH 6.8. This study implies that 
differences in the absolute solubility of solutions of the three polymorphs persist over time.  
 
Figure 44 - Solubility of Polymorphs in Phosphate Buffer Solution; Kaneniwa et al. 
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Changes in solubility of the polymorphs have been measured over time by the following 
groups: 
  Kaneniwa et al., [26], indicate that the order of fastest initial dissolution rate is: beta, 
alpha, delta. Their rates of initial dissolution in buffer solution at different 
temperatures have been used in a technique to estimate the polymorphic transition 
temperature in Section 5.1. 
  Ibrahim et al., [16] indicate that the solubility of the different polymorphs converges 
to a value of about 2.2 mg/ml at 36°C in phosphate buffer solution over a period of 
between 0.25-1.0 days, however the solution of the beta polymorph remains slightly 
more concentrated across the entire measurement period of 4 days. 
  Tuladhar, [19], includes solubility curves collected over several days for the alpha, 
beta and delta forms dissolved in phosphate buffer at 37°C with and without the use 
of wetting agents. In these experiments an absolute solubility of 4-5mg/ml is 
determined. Both the beta and delta forms are shown to be slightly more soluble than 
the alpha form, and this gap remains after a period of 5 days. This solubility gap is 
eliminated through the addition of less than 1% of Tween
®80, described variously as 
a dispersing agent and as an emulsifier, which consists primarily of polyoxyethylene 
sorbitan monooleate. In a separate study, Tuladhar et al., [34], investigate the effect 
of particle size and compression on the dissolution of phenylbutazone, paying 
attention to the API’s polymorphic form. 107 
4.3  Role of Solvent 
 
The crystallization experiments conducted during this investigation may be divided into the 
following classes: 
  Solvent screening experiments to ascertain solvent mediated transitions and identify 
solvate formation 
  Pure polymorph preparation according to developed procedures 
  Single crystal growth in expectation of a particular form or forms 
 
Solvent trials not only reveal the existence of solvated structures, but have brought to light 
the existence of new polymorphic forms as well. Furthermore different solvents are routinely 
observed to have a major impact on the morphology of the crystals formed, [70], a factor of 
major importance in the preparation of crystals suitable for single crystal X-ray diffraction.  
The objective of identifying conditions under which one polymorph of phenylbutazone 
crystallized in preference to another was also borne in mind.  
The choice of solvent seldom features in thermodynamic treatments of solvent crystallization, 
and specific consideration of solvent would not be anticipated, other than in those situations 
where the use of a particular solvent is associated with a change in enthalpy, resulting from 
causes such as: 
  Formation of a solvate 
  Formation of ions 
  Formation of hydrogen bonds 
  Reaction between the solvent and solute; e.g. uncatalyzed esterification of a 
carboxylic acid group by an alcohol, [93]. 108 
In common with many small organic drug molecules, phenylbutazone forms solvate 
structures with many crystallization solvents, and exhibits wide variations in crystal habit 
depending upon the solvent employed. Ascertaining clear patterns between the solvent 
employed, and the polymorphic composition of crystallized samples was far from 
straightforward.  
Under ambient conditions a number of solvents yielded pure alpha form, however in only 
very few instances was the pure delta form encountered. Moreover those solvents that gave 
rise to pure alpha form during one experiment could not necessarily be relied upon to yield 
pure alpha form upon repetition of the same experiment; the alternative outcome typically 
being a mixture of the alpha and delta polymorphs.  
In the following table the polymorphic outcomes of evaporative crystallization of 
phenylbutazone at ambient temperature and pressure are summarized for a range of common 
crystallization solvents. Samples were mixed at conditions below saturation, and filtered, 
before being allowed to crystallize in glassware open to the atmosphere.  
For a number of solvents, more than one experiment was conducted, and in several of these 
repeat experiments the effect of raising the starting temperature of the crystallization was 
observed.  
The most common polymorphic composition is indicated as well as other compositions that 
were encountered – concomitant mixtures of polymorphic forms are indicated by the names 
of the polymorphs present, separated by a forward slash. Solvents in which three or more 
crystallizations were carried out are indicated by an asterisk. 109 
Table 14 - Crystallization Results of Solvent Screening of Phenylbutazone
24 







       
Methanol*†  S  Alpha  Alpha/Delta, Delta 
Ethanol*†  S  Alpha/Delta  Delta, Alpha 
Iso-propanol  S  Alpha   
Acetone*  R  Alpha  Alpha/Delta 
Methylethylketone*  R  Alpha  Alpha/Delta 
Methyl-iso-butylketone  R  Alpha   
Cyclopentanone  R  Solvate   
Cyclohexanone*  R  Solvate   
Propylene carbonate  R  Solvate   
Methylacetate  R  Alpha   
Ethylacetate  R  Alpha/Delta   
Diethylether  S  Alpha   
Di-iso-propylether  S  Alpha   
Di-n-butylether  S  Alpha   




Chloroform  R  Solvate   
Tetrahydrofuran*  R  Solvate   
n-Heptane*†  S  Alpha/Delta  Alpha/Beta/Delta, Alpha/Beta, 
Alpha 
Benzene  R  Solvate/Alpha   
Toluene*†  R  Alpha/Delta  Alpha/Delta/Beta, Delta 
p-Xylene*†  R  Alpha/Delta  Alpha 
o-Xylene*†  R  Alpha/Delta  Alpha/Beta/Delta 
*Three or more crystallizations were carried out using this solvent. 
†Crystallizations at above ambient start temperatures were carried out using this solvent. 
§Pure beta form occurred as a side bloom around the edge of the crystallization dish. 
                                                           
24 Excludes crystallization experiments involving multiple solvents and/or antisolvents; e.g. methanol & water. 
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4.4  Targeted Crystallization of Polymorphs 
 
Grant et al., [94], state their belief that “solvent-mediated polymorphic transformation is an 
efficient technique to obtain the most stable polymorph”. Using the example of 
sulphamerazine, they go on to surmise that the selection of suitable solvent(s) to effect the 
desired polymorphic outcome of a given solute is determined by its degree of solubility and 
the strength of solvent-solute interactions; particularly hydrogen bonding. Rather than 
preferential solubility; (Section 4.1), the postulated mechanism of formation of a particular 
polymorph is kinetic control of nucleation events, influenced by stirring rate and temperature 
among other factors.  
Blagden and Davey, [95], also emphasize the importance of solvent selection, whereby a 
specific solvent is chosen in order to give rise to a solvent/solute pairing, which favours a 
certain packing “motif” of the crystal lattice. During nucleation and lattice formation, these 
“motif” sub-units form the basis of the lattice of a specific polymorphic form. The addition of 
secondary, inhibiting, solvents is introduced as a simultaneous tactic by which to prevent the 
formation of unwanted sub-units, inasmuch as their formation can be anticipated. 
Examples of the lack of predictability of the polymorphic composition of individual 
crystallization batches are not difficult to find. Threlfall, [96], recounts an experiment, in 
which preparation of specific polymorphs of twenty pharmaceutical active ingredients from 
well-described “recipes” was attempted, but which resulted in the expected outcome in only 
ten of the twenty cases.  
In a further example of unpredictability, Threlfall draws attention to a method of preparing 
polymorphic form I of sulphathiazole using n-propanol, which had been employed for several 
decades, but which no longer yields that polymorph with regularity.  
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4.4.1  Theoretical Background 
 
The changes in crystallization outcomes of established preparation methods described by 
Threlfall, underscore the complexity of solvent/solute interactions. However the very fact that 
a particular solvent is specified in a recipe, and yields reproducible polymorphic outcomes 
over an extended period of time, lends support to the conviction of Grant et al. about the 
effectiveness of solvent selection methods. 
In a review that explores the factors that give rise to different crystal forms, and concomitant 
mixtures in particular, Bernstein et al., [97], employ the term “occurrence domain” to denote 
the set of crystallization conditions in which a particular polymorph is formed. Concomitant 
crystallization of two or more polymorphs is an instance in which the occurrence domains of 
two or more polymorphs happen to overlap. The review concedes that although, “this domain 
exists for every substance, rarely if ever are its contents completely known”. 
In his more recent IUCr monograph on polymorphism, [1], Bernstein resorts to a probabilistic 
approach in order to explain the formation of a particular polymorph under a given set of 
conditions. In this framework preferential nucleation, rather than solubility, is the mechanism 
for the formation of a specific polymorph.  
Equation 30 - Probability Expression for Formation of Polymorph, i. 
 
      , i P i f G R   
 
The key variables are the free energy change associated with formation of polymorph, i, and 
kinetic rate function, R, for nucleation of the polymorph. As an example of R, Bernstein cites 
the rate expression principally attributed to Volmer and frequently referred to as the classical 
theory of nucleation from homogeneous solutions, which is expressed as follows: 112 
Equation 31 - Classical Nucleation Rate Equation from Homogeneous Solution 
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Where: 
J = Rate of nucleation 
A = Pre-exponential factor 
γ = Surface free energy 
ν = Molecular volume 
k = Boltzmann constant 
T = Temperature 
σ = Degree of supersaturation 
 
The expression for the rate of nucleation above is similar to the general Arrhenius rate 
equation, which is used to characterize the relationship between the kinetic rate constant, k, 
for various processes including crystallization, dissolution and reaction and the temperature at 
which those processes are carried out. 
 
Equation 32 - Arrhenius Expression for the Kinetic Rate Constant 
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Where: 
A = Pre-exponential factor 
E = Activation energy 
R = The gas constant 
T = Temperature 113 
The free energy term, ΔG, is substituted out of the expression for the rate of nucleation; in the 
case of non-electrolytes; the Gibbs-Thomson relationship is frequently employed for this 
purpose. A full derivation is provided by Mullin.  
Besides preferential nucleation, Bernstein also attributes the preferential appearance of one 
polymorph versus another to differences in the size of the activation energy barrier of 
formation of the individual polymorphs, a variable in the Arrhenius expression. Only the 
polymorph with the lower barrier would be expected to form, providing that the activation 
energy barrier of the other polymorph is not exceeded. 
Unlike the comparison of activation barriers of individual polymorphs, inspection of the 
nucleation rate expression indicates that the values of J for a pair of polymorphs may 
intersect over a range of supersaturation degrees. Bernstein gives examples, which suggest 
that two polymorphic forms of a molecule may each display higher rates of nucleation at 
different degrees of supersaturation.   
Threlfall postulates that crystallization processes may be divided into two categories, those 
which are under: 
  Kinetic control, in which case the choice of solvent is important 
  Thermodynamic control, in which case the choice of solvent is not relevant 
 
The results of the solvent screening experiments of phenylbutazone; (Table 14), indicate that 
the polymorphic outcomes is more dependent upon the choice of solvent than the temperature 
at which crystallization is carried out. This suggests that the mechanism of formation of 
polymorphs of this substance is under kinetic control. More detailed experiments involving 
phenylbutazone’s crystallization behaviour in a particular solvent are presented in the 
following section. 114 
4.4.2  Observed Crystallization Behaviour of Phenylbutazone 
 
A recent study concerning the crystallization behaviour of phenylbutazone under conditions 
of supersaturation, [98], was carried out at the University of Minnesota. In these experiments, 
conducted on methanol solutions of phenylbutazone, supersaturated solutions were prepared 
in scintillation vials at temperatures close to the boiling point of methanol, and then allowed 
to cool until reaching the desired crystallization temperature, at which temperature they were 
maintained until crystallization had completed. The degree of supersaturation is defined as 
the ratio of actual supersaturation concentration to the saturation concentration.   
The prevalent crystallization outcome is formation of the alpha or delta form or a mixture of 
the two. Datta and Grant point out the marked tendency of formation of the delta form at very 
high levels of supersaturation above a certain temperature. The results of that study are 
shown in the following table. 

















-20  ʱ  ʱ  ʱ  β + δ  β  β 
4  ʱ  δ  ʱ + δ  ʱ + δ  ʱ  ʱ 
12  ʱ  ʱ  ʱ  ʱ  ʱ + δ  δ 
20  ʱ  ʱ + δ  ʱ + δ  ʱ + δ  δ  δ 
30      δ  δ  δ  δ 
40      δ  δ  δ  δ 
50        δ  δ  δ 
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Among the interesting aspects of this study is the finding that at sub-ambient conditions it is 
possible to encounter formation of the beta form of phenylbutazone during unstirred 
crystallization; an outcome also encountered by Kaneniwa et al., [27].  
Efforts to reproduce the formation of the pure delta form via the preparation of supersaturated 
solutions during the course of this investigation were not successful, owing primarily to the 
difficulty of achieving stable solutions with the high levels of supersaturation indicated. 
Nucleation tended to occur spontaneously and crystallization would then progress to 
completion in the space of only a few minutes, yielding either pure alpha form or 
concomitant alpha/delta mixtures. 
 
4.4.3  Preparation of Pure Phenylbutazone Polymorphs 
 
The methods used to obtain pure polymorph samples are given in the following sub-sections. 
4.4.3.1  Alpha Form 
 
The use of ketone solvents typically resulted in formation of the pure alpha form. 
Concomitant alpha/delta mixtures were nonetheless encountered on occasion; upon 
recrystallization in ketone solvent, these mixtures were converted to pure alpha form. Similar 
results were obtained using ester solvents. 
4.4.3.2  Delta Form 
 
Reliable solvent-mediated formation of the delta polymorph, the most stable polymorph, was 
an elusive goal. The most promising solvent was toluene, from which pure delta form was 
crystallized on more than one occasion. However repeated crystallizations from toluene at 
differing start temperatures most frequently resulted in the formation of concomitant 
alpha/delta mixtures. When a small amount of unsaturated toluene solution was crystallized 116 
in a glass container, pure delta polymorph was obtained with some reproducibility; in most 
but not all cases a film of delta form was deposited on the floor of the container. By contrast 
pure delta form was obtained with complete reliability by heating of the solid alpha or beta 
forms at a temperature above their respective transition temperatures; (Section 5.2.1). 
Efforts to obtain pure delta form under the conditions described by Tuladhar using n-heptane 
as crystallization solvent were not successful. 
4.4.3.3  Beta Form 
 
As outlined in Section 1.3.3, the beta polymorph was formed without the use of stirring in 
only one set of experiments. When using the solvent methyl-tertiary-butylether traces of the 
beta form occurred in a bloom that formed around the edge of the evaporation dish; the centre 
of the dish contained the alpha and/or delta polymorphs. This occurrence may be regarded as 
a case where Ostwald’s Rule of Stages is obeyed; i.e. a crystallization event does not lead to 
the formation of the most stable polymorph, but rather to the polymorph, whose formation is 
accompanied by the smallest loss in free energy.  
The formation of the beta form from warmed methanol solutions using water as antisolvent 
often yielded beta form in concentrations of 90% or higher. In this technique the formation of 
the beta form is favoured by the use of water-soluble solvents such as alcohols, which remain 
in a homogeneous mixture with water, while precipitation of the solute is taking place.  
The results of a battery of control experiments intended to isolate the conditions, under which 
pure beta polymorph is formed, were less than conclusive. Raising the temperature, to which 
the methanol solution was heated, prior to precipitation of the phenylbutazone with water, did 
not lead to a clear pattern. Variations in the ratio of water to methanol had a more pronounced 
effect. These results are presented in the following table: 117 
Table 16 - Crystallization Outcomes of Stirred Methanol/Water Solution Experiments 
Batch  Precipitation 
Temperature 
Methanol/Water Ratio  Outcome 
1  55  1:1.25  Pure Beta 
2  55  1:2.5  Pure Delta 
3  55  1:5  Pure Beta 
4  45  1:2.5  Pure Delta 
5  62  1:2.5  Mostly Beta; <5% Delta 
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5  Transitions of Polymorphs and Solvates 
 
5.1  Predicting Transitions 
 
Transitions between polymorphs have been examined in detail for many materials, 
particularly in the context of studies of storage stability. In certain cases transitions occur at 
temperatures close to those of typical storage conditions, thereby raising the possibility that a 
delivery form may actually change partially or completely from the manufactured 
polymorphic form(s) to a different polymorphic form(s) along the supply chain.  
A frequently cited example is that of the pharmaceutical, chloramphenicol palmitate, a 
material that undergoes solid-state transition; i.e. transition does not involve a melting event.  
A polymorphic transition occurs at around 340K, [99], and the various polymorphic forms 
display differing bioactivities. 
Less frequently encountered are transitions, in which melting plays a role, [42]. In these cases 
a particular polymorph enters the liquid phase, from which a different form solidifies; a form 
exhibiting a higher melting point.  
The majority of polymorph transitions are irreversible, but examples of reversible changes 
are mentioned in the literature. Desolvation events represent still another class of transition; 
these are generally irreversible also.  
The existence of solid-state polymorphic transitions has been documented most extensively 
by Burger and Ramberger, [25, 100], and is implied in the thermodynamic treatment of 
polymorphic phases presented by Bernstein among others. But to what extent can 
thermodynamic properties of a polymorphic molecule actually enable the temperature of 
transition between polymorphs to be predicted? 119 
Derivations of a thermodynamic model to predict the temperature, at which polymorphic 
transition occurs, typically start from the Helmholtz relationship; (Equation 23).  For a 
molecule with two polymorphic forms A and B at temperature, T: 
  A A A G H T S   
     B B B G H T S   
 
At the temperature of transition, Ttrans, where polymorph A transforms to polymorph B, the 
free energies of the two polymorphs are assumed to be equal; i.e.  0 AB G    and the two 
equations above may be added to give the following expression: 
   0 A B A B trans A B G H T S           
The quantity  AB G    has been widely estimated by considering the thermodynamic behaviour 
of the two polymorphs in solution, using measured solubility data in a particular solvent at 
the transition temperature, Ttrans. When a pair of polymorphs is equally soluble, the 
polymorphs share the same free energy, G, and, at this temperature, solid-state transition 
between the two forms may be expected to occur. For such a transition the following 
relationship is derived from Equation 22: 
















R = The gas constant 
Ttrans = Temperature of polymorphic transition, A → B 120 
(SolA)trans = Solubility of polymorph A at transition temperature, Ttrans 
(SolB)trans = Solubility of polymorph B at transition temperature, Ttrans 
 
Evidently this method of calculating the transition temperature is most readily applied in 
cases where solubility data for individual polymorphs have been collected at several 
temperatures, and where the resulting solubility curves show an intersection. Gu and Grant 
recommend the use of dissolution rate values as an alternative to solubility values, [101].  
For phenylbutazone both solubility and dissolution rate have been measured across a range of 
different temperatures in a variety of different solvents; (Section 4.2.3). Instances of 
solubility curves intersecting for the polymorphs are rare, but one example occurs in the 
measurements made by Kaneniwa et al., [27]. Using these solubility values, plots of ∆G vs. 
temperature have been prepared for both  G    and  G   . These are shown in the 
following figure: 
 
Figure 45 - Free Energy Change vs. Temperature for Alpha-Delta and Beta-Delta Transitions 
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According to this methodology, the transition from the alpha to the delta form is predicted to 
occur at about 307K. The transition of the beta to the delta form does not occur in the 
temperature range of dissolution measurements carried out by Kaneniwa et al., however the 
trend in the lower temperature readings suggest that transition would be predicted to occur at 
about 320K (47°C). 
Other groups have developed modified methods to calculate the transition temperature using 
solubility data: 
i.  Urakami et al., [102], derive an expression for the transition temperature, Ttrans, using 
the solubility ratio for the two polymorphs at only one measurement temperature, T1. In this 
approach the free energy difference between polymorph A and B,  AB G   , is calculated at the 
































This yields the following expression for Ttrans: 
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This method allows tabulated solubility ratios between polymorphs such as the values 
compiled by Pudipeddi et al., [91], to be employed directly.  122 
Again the solubility data in buffer solution measured by Kaneniwa et al. have been used to 
calculate the actual solubility ratio at a range of different temperatures. These solubility pairs 
for the polymorphs at each of the measurement temperatures are plotted in the following 
figure, together with the predicted transition temperature obtained from each pair of solubility 
values. Evidently this method does not rely on an intersection of the measured solubilities for 
the two polymorphs. 
Figure 46 - Solubility & Predicted Transition Temp. Vs Measurement Temp. 
 
ii.  Gu and Grant, [101], modify the technique of estimation of ∆G from solubility 
values by introducing the enthalpy of solution of polymorph A and B at the same 
temperature, T, in the same solvent; the enthalpy of transition is not employed: 
   / S H G T      123 
The enthalpy term is then expressed as 
AB sol sol HH   , so that: 
 
    /
AB B A sol sol B A S H H G T        
 
At the transition temperature, Ttrans, the free energy is zero, and therefore: 
 /
AB B A sol sol trans S H H T       
Rearranging: 
   /
AB trans sol sol B A T H H S       
Substituting out the entropy term:   














Gu and Grant then replace the free energy term by the solubility ratio expression discussed 
earlier to give: 
Equation 35 - Transition Temperature Calculation after Gu & Grant 
 




















25 together with the heat of solution and solubility values presented by 
Kaneniwa et al. for the transition from form alpha to form delta of phenylbutazone, the 
transition temperature, Ttrans, is calculated to be 369K. 
                                                           
25 Reference temperature is 298K. 124 
5.2  Measurement of Transitions 
 
The storage stability of phenylbutazone’s polymorphs has been examined over extended 
periods by Matsuda et al., [24], who report no signs of transitions between polymorphs at 
room temperature over the course of several years. At temperatures above 40°C, however, the 
same group indicates that the beta and alpha forms change gradually to the delta form over a 
period of several months. These transitions are accelerated by the presence of atmospheric 
humidity.  
Other groups confirm changes in form based upon DSC scans of the individual polymorphs; 
e.g. Müller, [18]. Endotherms that do not correspond to the main melting event are readily 
apparent on DSC scans of the alpha and beta forms of phenylbutazone carried out in-house 
on the Netzsch Jupiter
®. To shed light on the transition behaviour of phenylbutazone’s 
polymorphs and solvates, three types of experiment were undertaken: 
a) Room Temperature Storage - Long-term stability at room temperature was tested by 
repeated PXRD scans at intervals of a couple of months. Lozenge shaped samples, with 
one face open to the atmosphere, were stored in a large bell jar maintained at room 
temperature. 
b) Isothermal Heating – Powder samples were heated isothermally in an oven for periods of 
a number of hours, and then returned to sample holders, and re-examined by PXRD to 
ascertain whether a transition had occurred. The heating temperature was set a little below 
the melting temperature; prior DSC scans also provided indications of suitable temperature 
levels. 125 
c) Stepped Heating, in situ PXRD Scans - Collection of PXRD patterns was conducted in 
sequence at temperatures up to the melting event, using a nitrogen stream for both heating 
and cooling. Polymorphs were examined in sealed capillaries, whereas solvates were 
examined in open capillaries to allow the solvent to escape. Thanks to the use of the wide-
angle detector, it was possible to complete PXRD scans across an adequate 2theta range in 
time periods of 10-20 minutes. The temperature of the capillary was then increased 
incrementally, and allowed to stabilize at the new set point, involving the elapse of a 
matter of minutes, before the sample was rescanned. In certain cases the sample was 
recooled to check for reversible form changes. Low temperature measurements were also 
undertaken in search of sub-ambient temperature transitions. 
 
5.2.1  Results for Polymorphs 
 
5.2.1.1  Room Temperature Storage 
No change was observed in the polymorphic composition of the alpha, beta or delta forms of 
phenylbutazone over a period of six months or more. This concurs with the findings 
presented in the kinetic study of Matsuda et al.. 
5.2.1.2  Isothermal Heating 
No change in the delta form PXRD pattern was apparent subsequent to the heating cycle. In 
the cases of the alpha and beta forms, a complete transition to the delta form occurred after 
heating at a temperature above the transition temperature within the space of an hour. No 
remaining traces of alpha and beta peaks are apparent in the respective PXRD patterns after 
the transition has taken place.  126 
5.2.1.3  Stepped Heating, in situ PXRD Scans 
 For the alpha and beta polymorphs, complete transition to the delta form took place within 
the time frame of the temperature increase and equilibration steps. In both cases, the 
temperature at which transition occurred, matched the temperature of the observed non-
melting endotherm in the corresponding DSC scan. The sequences of PXRD patterns are 
shown in the following figures.  
For both the alpha-delta and beta-delta transitions, subsequent to transition, the samples were 
recooled to below the transition temperature. In neither case was a reversion to the original 
polymorphic form found to take place. 
Figure 47 - PXRD Patterns of Alpha Form at Stepped Temperatures
26 
 
                                                           
26 Post-transition patterns have been offset to improve visual clarity in many of the figures in this section 127 
Figure 48 - PXRD Patterns of Beta Form at Stepped Temperatures 
 
 
5.2.2  Results for Solvates 
 
Apart from the sealing of capillaries for the collection of stepped temperature PXRD patterns, 
the procedures employed for the solvate samples were identical to those for the polymorphic 
forms. 
5.2.2.1  Room Temperature Storage  
 
Changes in crystal form were observed in certain of the solvates over a period of six months 
or less. Among the solvates that did exhibit changes, transitions gave rise to a mixture of 
known polymorphs; decomposition typically occurring from one measurement to the next 
with few major changes, if any, being observed in later PXRD patterns.  128 
This behaviour is apparent in the series of PXRD patterns collected over a ten month period 
from a sample of the solvate with tetrahydrofuran, (b.p. 66°C). A transition of the solvate to a 
mixture of the beta and delta forms is observed to take place; the transition is largely 
complete within the period of a month.  
Figure 49 - Decomposition of Tetrahydrofuran Solvate over Time 
 
Transitions were also observed among other solvates formed with low-boiling solvents after 
periods of room temperature storage. Repetition of certain of these stability tests indicates 
that the period of decomposition of individual solvates is not constant. In one example, the 
solvate formed with methyl-tertiary-butylether, a transition took place in time periods of as 
little as one week, while in a few instances, batches of the same solvate remained unchanged 
for periods of several months, even when stored in an open sample container.  129 
PXRD patterns of a specimen of the methyl-tertiary-butylether solvate collected over the 
course of 7 months are shown below; an amount of the solvate is evidently still contained in 
the decomposition product.  
 
Figure 50 - Decomposition of Methyl-tertiary-butylether Solvate over Time 
 
 
The solvate with cyclohexanone (b.p.156°C) was also tested, and was found to be unchanged 
after several months of storage. Similar behavior is presumed for the solvates with 
cyclopentanone and propylene carbonate, which also have boiling points well above the 
melting temperature of phenylbutazone. 130 
5.2.2.2  Isothermal Heating   
 
The solvates with cyclohexanone (b.p. 156°C) and with propylene carbonate (b.p. 240°C) 
undergo complete transition to the delta form after 2 hours of heating at 90°C. For the 
propylene carbonate solvate, the patterns before and after heating are shown below. 





A sample of the solvate with methyl-tertiary-butylether was heated isothermally at 90°C. 
After an hour there is no sign of the major solvate peaks, however there is a visible shoulder 
in the delta peak at 2θ = 8.15ﾰ, suggesting that another form is present; its position, 2θ = 8.3°, 
matches the largest peak position of the beta form.  After two hours of heating, the peak 
shoulder has disappeared. The sequence of patterns is shown in the figure overleaf. 131 
Figure 52 - PXRD Patterns of MTBE Solvate before & after Heating 
 
 
5.2.2.3  In situ PXRD of Solvates at Elevated Temperatures 
 
There was no indication of the emergence of intermediate phases or polymorph mixtures in 
the stepped heating experiments conducted on phenylbutazone’s solvates. 
In the case of the tetrahydrofuran solvate, complete transition to the delta form took place in a 
single temperature increase interval. Whereas for the solvate with cyclohexanone changes in 
the PXRD pattern were observed as the melting point of the solvate was approached; the 
solvate’s melting point was found to be a little below the melting temperature of pure 
phenylbutazone. These results are presented in the figures displayed overleaf. 
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Figure 53 - PXRD Patterns of Tetrahydrofuran Solvate up to Transition to Delta Form 
 
 
Figure 54 - PXRD Patterns of Cyclohexanone Solvate up to Melting Temperature 
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5.3  Kinetic Considerations 
 
Carstensen, [90], postulates that polymorphic transitions may be divided into four classes of 
mechanism: 
a)  Probability of transition of individual molecules is independent; the fraction converted 
to the end product increases linearly from 0 to 1 over time. 
b)  The rate of transition is proportional to the amount of the starting form that has not yet 
changed form up to extinction of the start material. 
c)  The rate of nucleation of the new form changes over time
27 (in addition to the 
extinction of start material characterized in class b). 
d)  The above factors apply, and the geometry of nucleation events is taken into account; 
diffusion effects may also be considered. 
The extent of conversion of the start product into the end product is expressed in a 
proportional range between zero and one; typically designated by the Greek letter alpha, 
[103]. For transitions of crystal forms occurring in the solid state, in which species X changes 
into species Y upon heating, ʱ is commonly determined by the following techniques: 
  DSC - enthalpy flow is integrated over time; conversion is equivalent to the 
ratio of the integral enthalpy input to the total enthalpy input of the transition. 
  TGA - weight loss over time as a proportion of total weight loss is calculated. 
  PXRD - peak intensity changes are used to calculate actual polymorph 
concentrations at each point of the transition. 
                                                           
27 Galwey and Brown introduce five different types of nucleation mechanism each with its own expression for 
the rate of nucleation, namely: exponential, linear, instantaneous, power and branching. 134 
While the first two methods provide only an analogue of the concentration, the use of PXRD 
enables actual concentration values to be measured using conventional quantitative PXRD 
methods, [104-107]. Unlike thermal analysis, PXRD also provides explicit confirmation of 
the species present, and reveals the emergence of any intermediate phases. 
Examples of the use of powder X-ray diffraction to follow polymorphic transition events are 
less common, not least because of the inherent complication of the extended counting time 
required to collect a diffraction pattern over an adequate range of 2theta.  
Using in-house diffraction equipment, the shortest measurement interval for a complete 
2theta range is the 5-10 minute scan time of the wide angle detector available for use with the 
transmission geometry diffractometer. For materials such as phenylbutazone, which change 
form within the space of a few minutes, this represents a limitation. Studies of this nature 
have mostly been carried out on synchrotron beam lines with detection apparatus capable of 
recording a complete diffraction pattern in a minute or less, [108, 109]. 
Clearly thermogravimetric analysis is suitable only in those instances, where the transition 
under study is associated with a change in weight; e.g. desolvation or certain chemical 
reactions. DSC is the most frequently encountered method. 
Once a set of conversion data has been obtained, it may be used to identify the kinetic rate 
expression for the transition under examination. In “model-fitting” techniques, which are 
summarized by Khawam and Flanagan, [110], among others, [111], the general form of the 
kinetic rate expression combines the terms of the Arrhenius equation for the rate constant, k; 
(Equation 32), with a rate function, f(ʱ), which can be shown to fit the conversion curve of 
the transition under investigation. The general form of the reaction rate equation may then be 
expressed as follows: 135 








   
Where: 
ʱ = Proportional conversion to end product  
t = Time from start of transition 
f(ʱ) = Rate function that fits observed conversion of the reaction components 
 
For the case of constant nucleation with extinction of start material described earlier, the 
general form of the function for the change of species one, X, into species two, Y, is 
described in mathematical terms as follows: 
      XY   
Where: 
X = Moles of species one 
Y = Moles of species two 
[X] = Molar fraction of species one 
[Y] = Molar fraction of species two 
 
Taking into account that complete extinction may not occur, the start and end mass balance 
expressed in absolute molar terms is as follows: 
Start:    00 XY  constant   
End:  end end XY  constant 
And:          00 end end X Y X Y     136 
Expressed in proportional terms: 
Start:      00 1 XY   
End:      end end XY  1 
And:                         00 end end X Y X Y     
 
The mass balance at any point in the transition is simply: 
    XY  1 
 












If complete transition to the end product Y takes place from zero start concentration, then Y0 




    
Expressed proportionally:     Y    
 
Assuming that complete conversion occurs, 0 end YX  , and the rate at which transition occurs 
is directly proportional to the proportion of start material that is present; the highest rate of 
transition is at the start of the transition and declines for the duration of the transition, until X 
falls to zero.  137 
The rate function may then be expressed as follows: 






In proportional terms     1 YX   so that the rate expression may be re-expressed in terms 
of only the end-product or the proportional conversion: 











   
 
Substituting the rate constant, k, by the terms of the Arrhenius equation gives: 











This corresponds to a first order “order of reaction” model for the decomposition. Matsuda et 
al., conclude that the transition of the beta to the delta form follows this kinetic model.  
This derivation does not specifically take into account the nature of the nucleation of a given 
polymorph. Apart from DSC scans, which are shown in the next section, no real-time 
information is available about the manner in which the alpha and beta forms of 
phenylbutazone transform to the delta polymorph. Nucleation mechanisms may therefore 
only be inferred from DSC-based conversion curves. 
Hot-stage microscopy is one technique employed to observe polymorphic transitions in order 
to ascertain how nucleation takes place, however it does not form part of this study. 138 
From hot-stage microscope experiments Bernstein, [1], presents graphical examples of 
nucleation occurring in polymorph specimens. In these examples nucleation occurs either in a 
diffuse manner throughout the sample, or at a front that moves through the crystal. 
Nucleation by interface advance gives rise to power law rate expressions, [112], as distinct 
from the “order of reaction” model derived earlier in this section. 
As their name suggests, power law models raise the conversion factor, ʱ, by a power factor; 
e.g.   
  1 nn n 
 . They provide a good fit to integral conversion measurements for transitions 
that accelerate from start to finish.  
In the case of “order of reaction” models, acceleration of the transition from start to finish 
does not occur, because the rate of transition is proportional to the amount of start material 
remaining.  
Bernstein identifies two alternative nucleation mechanisms for transitions of this nature: 
  Random nucleation throughout the crystal 
  Nucleation at specific defects or crystal edges 
Brown, [103], identifies six stages in the progress of nucleation and growth across the surface 
of a material undergoing transition with nucleation initially taking place randomly; these are 
depicted for the 2-dimensional case in the figure displayed overleaf. 
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a)  emergence of nucleation sites  
b)  first nuclei formed 
c)  crystal growth and further nucleation 
d)  meeting of areas of crystal growth 
 
e)  ingestion of nucleation sites by crystal 
growth regions 
f)  continued growth 
 
 
This sequence gives rise to an acceleratory phase and a deceleratory phase. The following 
terminology is frequently used to describe these phases: 
  “the induction period” at the commencement of the transition 
  “the acceleration period” up to the inflection point of the conversion curve 
  “the decay period” of slowing conversion until conversion is complete 
                                                           
28 Reproduced from M.E. Brown, Introduction to Thermal Analysis, 2
nd ed., 2001, Kluwer, Dordrecht, p.184. 
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For transitions with this mechanism the cumulative conversion follows an S-shaped, 
“sigmoid” curve such as the one observed for the alpha-delta transition; Figure 57. A fuller 
derivation of this mechanism is provided by Galwey and Brown among others, [113]. 
The Prout-Tompkins equation and, more commonly, the Avrami-Erofeev equation (also 
known as the JMAEK equation) are used to fit sigmoid-shaped conversion curves: 
Equation 38 - “AN” Form of the Avrami-Erofeev Rate Equation 




kt      
Where n is an integer typically between 2-4. 
Whichever method is chosen to follow the progress of the transition under study, the heating 
programs employed are either:  
  Non-isothermal measurements typically along a constant heating gradient 
  Isothermal heating at a particular temperature over an extended time period 
In this investigation only ramped temperature measurements were carried out, and calculation 
of the Arrhenius parameters was not undertaken. Accurate evaluation of the kinetic 
parameters and the reaction order is inherently more difficult in non-isothermal experiments 
because the rate constant, k, changes during the course of the transition, owing to its 
dependence on the measurement temperature; ( Equation 32). 
Among techniques for establishing the rate relationship suitable for single experiment sets, 
The Handbook of Thermal Analysis presents a method which it attributes to Freeman & 
Carroll, [114, 115]. In this procedure the following equality is plotted, using the axis terms 
indicated. A line of best fit is then determined for the plotted points.  141 
Equation 39 - Non-isothermal model fitting function of Freeman & Carroll 
      ln ln(1 ) 1
a E
d dT n T
R
       
From this expression the following terms are obtained for use as the axis coordinates:  
 
     
 
ln 1






   
 
A good fit between the measurement points and the best fit line confirms that the rate 
function is indeed of the form;    ( ) 1
n f   . Although this technique requires only a small 
amount of experimental data, Brown points out that it is not conclusive; a straight line can be 
indicative of a number of different models including those with power law and Avrami-
Erofeev rate equations. 
This technique is employed to fit the conversion values for the alpha-delta polymorph 
transition, which is examined in the following section. 
 
 
5.4  Transitions of Phenylbutazone during Constant Gradient Heating 
5.4.1  Polymorphs 
5.4.1.1  Alpha Form 
 
A DSC scan of a sample of the alpha form, heated in a rising temperature programme at a 
constant ramp rate of 10K/minute, displays two clear endotherms; see Figure 56. 
In situ X-ray diffraction experiments explicitly identify the endotherm that commences at 
approximately 85°C as corresponding to a transition from the alpha form to the delta form. 
The second endotherm corresponds to the melting event.   142 
Figure 56 - Alpha Form Transition & Melting Endotherm by DSC 




































From the in situ X-ray diffraction patterns, it is apparent that all the alpha form is transformed 
into delta form. The integral enthalpy change across the endotherm over time is therefore 
taken to be analogous to the proportional conversion, ʱ, displayed in Figure 57. 
The integral conversion plot appears to follow a sigmoid curve. Applying the Freeman & 
Carroll method described in the preceding section, yields the following plot from the end of 
the induction period of the transition, whose termination has been arbitrarily fixed at ʱ = 1%.  
 
Figure 58 - Plot of Kinetic Expression of Alpha-Delta Conversion after Freeman Carroll 

























The high value of the coefficient of determination, R
2, of the line of best fit indicates that a 
kinetic function of form,    ( ) 1
n f   , is valid for this transformation. The sub-unitary 
value of n, given by the axis intercept, coupled with the sigmoid shaped conversion curve 
suggests that an Avrami-Erofeev model is applicable to this transition. This supports the 
conclusion of Matsuda et al., and is consistent with a nucleation and growth mechanism. 144 
5.4.1.2  Beta Form 
 
The DSC scan of the beta form was measured at a temperature increase rate of 5K/min. It 
displays a clear melting endotherm apparent in the figure below, but only a very minor 
endotherm at the temperature where in situ X-ray diffraction experiments identify that the 
beta form transforms to the delta form. These diffraction patterns confirm that little or no 
delta form is present at the temperature at which the corresponding DSC endotherm 
commences, and that complete extinction of the beta form occurs by the end of the transition 
event. Owing to the small size of the transition endotherm, confirmation of the first order 
kinetics postulated by Matsuda et al. was not attempted. Variations in the enthalpy of this 
transition are discussed in the next section.  
 
Figure 59 - Beta Form Transition & Melting Endotherm by DSC 



















In situations such as these Bernstein, recommends the use of hot-stage microscopy, noting 
that “there may be optically observed phase changes that are barely detectable by other 
analytical techniques such as differential scanning calorimetry.”  145 
5.4.1.3  Delta Form 
 
The delta form was not observed to transition to other polymorphs upon heating during X-ray 
diffraction experiments. Its DSC scan displays only a melting endotherm; (Appendix 2). 
5.4.2  Solvates 
 
For the solvate formed with tetrahydrofuran (b.p. 66°C), the behaviour upon heating was 
similar to that of the alpha and beta polymorphs. At a temperature ramp rate of 5K/min, the 
solvate transformed to the delta form of phenylbutazone without a visible melting event. 
Subsequently the sample melted at 105°C, the melting temperature of the delta polymorph.  
Figure 60 - DSC Scan of Tetrahydrofuran Solvate 



















Similar behaviour was observed of the solvates with methyl-tertiary-butylether, (b.p. 55°C) 
and with the high-boiling solvent, propylene carbonate (b.p. 240°C). 146 
For the solvate formed with cyclohexanone, (b.p. 155°C), at a temperature ramp rate of 
5K/minute, no transition is observed before melting, which occurs at 95°C; i.e. below the 
melting point of the delta form. The reduction of the melting temperature is also apparent in 
the corresponding in situ PXRD patterns; (Figure 54).  
Figure 61 - DSC Scan of Cyclohexanone Solvate 
















5.5  Discussion of Results 
5.5.1  Polymorphs 
 
From the elevated temperature X-ray diffraction patterns of the alpha and beta polymorphs; 
(Section 5.2.1.3), it is readily apparent that full transition to the delta form has taken place, 
and that transition is completed in a matter of minutes after a particular temperature increase 
step has been carried out. At the temperature step immediately below the transition event, 
there is no indication from the PXRD patterns that even partial transformation takes place 
within the space of the half hour needed to achieve equilibrium and collect the PXRD pattern. 147 
Rising temperature heating of the alpha and beta polymorphs across the same temperature 
range in the differential scanning calorimeter shows up the presence of an additional 
endotherm to the melting endotherm, albeit only a very small one in the case of the beta form.  
From the shape of these additional endotherms it is assumed that the transition event is 
completed in about a minute. The following table summarizes the temperatures of transitions 
between forms of phenylbutazone measured by different groups: 

















Alpha to Delta  360-70   350  373-376  366.4 
Alpha to Beta  Not observed  330 ± 20  n/a  n/a 
Beta to Delta  365-68   360  n/a  368.1 
 
In their compilation of transition events of pharmaceutical active ingredients, Burger and 
Ramberger, indicate that at about 330K the alpha form changes to the beta form, which in 
turn changes to the delta form. A transition from the alpha to the beta form did not become 
apparent during the stepped temperature PXRD experiments conducted in-house.  
The divergences in measured transition temperatures may result from differences in the 
heating gradient of the different experiments. Forni et al., [116], demonstrate the impact that 
heating rate causes on measurement of the melting temperature of the delta form. 
                                                           
29 This group use the Roman numeral designations for the polymorphs adopted by Müller, however the form 
numbers of alpha and beta have apparently been reversed, so that; I is delta, II is beta and III is alpha. 148 
The Proteus
® analysis software for the Netzsch Jupiter
® DSC enables the size of enthalpy 
changes associated with polymorph transitions to be assessed from transition endotherms in 
the same manner that heats of fusion are obtained from melting point endotherms.  The 
values of the polymorph transition endotherms of the alpha and beta forms as well as those of 
melting events are shown in the following table together with literature values: 




















Alpha to Delta  23.7        6.5 ± 1.6 
Alpha (Delta) Melting   29.8  119.32    79.3  79.3 
Beta to Delta  0.6        -1.6 ± 0.6 
Beta (Delta) Melting   91.4  88.36    71.1  71.1 
Delta Melting  90.9  93.41  107.96  72.3  72.3 
 
A number of aspects of the data contained in this table deserve mention: 
  There is wide variation between the values reported by different researchers. 
  The value of the alpha melting endotherm recorded in-house is much smaller than 
the other two values reported in the literature. 
  The size of the alpha-delta transition endotherm recorded in-house is much larger 
than that reported by Burger & Ramberger. 
  Burger and Ramberger indicate the transition of the beta to the delta form is 
exothermic. 149 
Müller provides the results of three DSC 
scans of the beta form at different heating 
gradients. These indicate that, for the beta 
polymorph at least, the rate of heating 
severely influences the size of the 
transition and melting enthalpies.  
At the slowest ramp rate, 2K/min, the 
observed transition endotherm is very 
small, but the melting endotherm is 
apparently enlarged. Conversely, at the 
largest heating gradient, 20K/min, the 
transition endotherm is large, but the size 
of the melting endotherm is diminished. 
 
In a review of the transition behaviour of several APIs, the influence of a solid-state 
polymorphic transition in the vicinity of the melting point is examined by Giron, [42]. The 
period of heating near the transition temperature is shown to influence the size of the 
transition endotherm. This suggests that the polymorphic transition and nearby melting event 
are to some extent interrelated, and raises questions about the nature of the transition 
mechanism.  
Possible variations in the kinetic parameters and methods to characterize their effect upon 
measured thermal properties of pharmaceutical compounds are discussed by Khawam and 
Flanagan, [110]. Exploring these methods is beyond the scope of the present investigation. 
Figure 62 - Beta Transition & Melting - Müller 150 
5.5.2  Solvates 
 
Upon heating, those solvates containing solvents, whose boiling points are below the melting 
temperature of phenylbutazone, were observed to desolvate completely, leading to formation 
of the delta form before melting.  
This contrasted with the thermal behaviour of at least one solvate with a high-boiling solvent, 
however the observed differences depended upon the heating programme employed. When 
submitted to swift temperature rise during in situ PXRD experiments and DSC scans, the 
solvate with cyclohexanone retained its solid/liquid lattice, until melting of the combined 
solvate occurred. Weight loss of the sample continued to occur for some time after the 
melting event, which is consistent with subsequent evaporation of solvent from the mixture of 
solvent and melted solute. By contrast, isothermal heating of the same solvate at 90°C; (i.e. 
well below the solvent’s boiling point), over the course of two hours gave rise to formation of 
the delta polymorph. This indicates that evaporative solvent loss eventually leads to 
desolvation and formation of the delta form; a conclusion supported by the analogous 
behaviour under isothermal heating at 90°C of another solvate with a high-boiling solvent, 
the solvate with propylene carbonate. This solvate was not examined by DSC or by in situ X-
ray diffraction to confirm that it too retains its solvate lattice, when subjected to a rapid 
temperature increase, however this result is anticipated. 
No desolvation events were observed upon extended room-temperature storage of the 
solvates with high-boiling solvents that were tested. Desolvation transitions of a number of 
solvates with low boiling points did take place upon extended room temperature storage; the 
time period up to transition was observed to be variable. Conditions that triggered the onset 
of desolvation did not become clear during the experiments that were conducted.  151 
Conclusions 
 
During this investigation, in which only pre-prepared phenylbutazone was used as starting 
material, a fully reliable solution crystallization technique for the formation of the pure delta 
polymorph was not identified. This difficulty seems counter-intuitive, in light of the fact that 
the alpha and beta polymorphs transform to the delta form in the solid state. One researcher, 
Tuladhar, has documented a solution crystallization method that resulted in formation of pure 
delta form, but this result could not be reproduced. 
The delta polymorph displays no tendency to change to the other crystal forms in the solid 
state, which suggests that the delta form is the most stable polymorph. Neither comparison of 
the calculated densities of the alpha and delta forms, nor invocation of Ostwald’s Rule of 
Stages provides a decisive indicator of the relative stability of the alpha/delta pair, however. 
The Rule of Stages does support the hypothesis that the beta polymorph is less stable than the 
alpha or delta forms. 
The preferential solubility model of polymorph formation does not appear to be a useful 
guide to predicting the formation of particular phenylbutazone polymorphs during solution 
crystallization, even though differences in the solubilities of individual polymorphs have been 
measured, and have been demonstrated to persist over time. 
 Solvent choice does have a reproducible impact on polymorph composition in certain cases, 
and it is presumed that the progress of crystallization is subject to a kinetic rather than a 
thermodynamic control mechanism in many, if not all, instances. 
The ability to produce pure delta form completely reproducibly from the alpha and beta 
polymorphs, by isothermal heating above the temperature of transition, makes this technique 152 
the most reliable method to prepare pure delta form. This method was not observed to result 
in the formation of a liquid phase; the identified transitions occur entirely in the solid state. 
Based upon DSC-derived conversion values, the kinetic function for the alpha-delta transition 
appears to adhere to an Avrami-Erofeev model, and this is consistent with the findings of a 
previous study. 
The results of DSC experiments on the established polymorphs present a conundrum; large 
variations exist in the enthalpies of fusion and of polymorphic transition measured by 
different research groups. From the limited amount of DSC data that has been collected 
during this investigation, the supposition is made that the proximity of the transition 
temperatures of the alpha and beta form to the temperature of the melting event means that 
the two events should not be considered as being entirely independent. This would explain 
the measurement of a high value for the transition enthalpy of the alpha-delta transformation 
and the depressed value of the measured enthalpy of the subsequent melting endotherm. 
Variability in the kinetic parameters of the transitions is also put forward as a possible 
explanation of these results. In situ synchrotron PXRD experiments on phenylbutazone’s 
polymorphs would very likely provide valuable, supplementary information about the speed 
and conversion path of these transitions. 
In the case of phenylbutazone, the comments of Borka & Haleblian, concerning the 
superiority of PXRD as a means of polymorph identification, appear to be borne out. Indeed 
it is not unlikely that attempts to identify polymorphic forms by differential scanning 
calorimetry may have contributed to confusion in the identification of certain polymorphs 
during past investigations of this molecule.   
The other crystal forms of phenylbutazone mentioned in the literature, most notably the 
gamma, epsilon and zeta forms, were not positively identified during solvent crystallizations 153 
carried out during this investigation. However preliminary grinding experiments confirmed 
that changes occur in relative intensities of diffraction peaks of the known crystal forms. 
Only one researcher, Tuladhar, has reported that crystals of any of these novel forms can be 
prepared by conventional crystallization methods, which would constitute a reasonable basis 
for optimism that crystal specimens suitable for single crystal X-ray diffraction may be 
isolated. In view of the difficulty in growing high quality single crystals of even the 
established polymorphic forms of phenylbutazone, it seems unlikely that complete structural 
information for novel form(s) and/or their modifications can be obtained from classical, 
single crystal X-ray diffraction experiments. 
This investigation identifies two new solvates, those formed with methyl-tertiary-butylether 
and with propylene carbonate, whose structures are determined to be monoclinic with space-
group C2/c, thereby confirming the finding of Hosokawa et al. that phenylbutazone forms 
several solvates that are isostructural with one another. In addition, two cyclic ketone 
solvents are also found to form solvates with phenylbutazone, and, based upon PXRD pattern 
matching, these solvates appear to have crystal lattices that are identical with one another. 
Although the full structures of these newly discovered solvates with cyclohexanone and with 
cyclopentanone could not be confirmed, it is likely that they are also isostructural with the 
seven other solvates with space-group, C2/c. 
Distinguishing discrete solvate structures by chemical formula units, there is as yet no clear 
indication that more than one solvate is formed between phenylbutazone and a given solvent. 
As evidenced by the low temperature PXRD pattern of the solvate with tetrahydrofuran, there 
is, however, good reason to believe that this solvate adopts more than one packing 
arrangement. 154 
The ability to calculate theoretical powder diffraction patterns from structural models of the 
crystal lattice represents a powerful means of validating structure solutions of individual 
crystal forms, but the implications of disparities, such as those that have come to light during 
investigation of phenylbutazone’s solvates, are not fully clear. The many reports of 
unconfirmed crystal forms of this and other important industrial materials serve to underscore 
the importance of full structure determination; be it via single crystal X-ray diffraction or via 
alternative methods. 
Uncertainty continues to surround the nature and the crystal structures of many of the 
polymorphs of phenylbutazone. Thanks to synchrotron PXRD experiments, progress has been 
made in determining the unit cell of phenylbutazone’s delta form. A plausible structural 









1.  Bernstein, J., Polymorphism in Molecular Crystals. 1 ed. IUC Monographs on Crystallography, 
ed. I.U.o. Crystallography. 2002, Oxford: Oxford University Press. 410. 
2.  Sharma, B.D., Crystal Systems & General Chemistry. Journal of Chemical Education, 1982. 59. 
3.  Sharma, B.D., Allotropes & Polymorphs. Journal of Chemical Education, 1987. 64. 
4.  Byrn, S., et al., Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. 
Pharmaceutical Research, 1995. 12(7): p. 945. 
5.  Yu, L.X., et al., Scientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated 
New Drug Applications. Pharmaceutical Research, 2003. 20(4). 
6.  Bauer, J., et al., Ritonavir: An Extraordinary Example of Conformational Polymorphism. 
Pharmaceutical Research, 2001. 18(6). 
7.  Yang, W., et al., Evaluation of phenylbutazone and poly(amidoamine) dendrimers 
interactions by a combination of solubility, 2D-NOESY NMR, and isothermal titration 
calorimetry studies. Journal of Pharmaceutical Sciences, 2009. 98(3): p. 1075-1085. 
8.  Price, S.L., The Computational Prediction of Pharmaceutical Crystal Structures and 
Polymorphism. Advanced Drug Delivery Reviews, 2004. 56: p. 301-319. 
9.  Gavezzotti, A., Are Crystal Structures Predictable? Accounts of Chemical Research, 1994. 27: 
p. 309-314. 
10.  Gavezzotti, A. and G. Filippini, Polymorphic Forms of Organic Crystals at Room Conditions: 
Thermodynamic and Structural Implications. Journal of The American Chemical Society, 
1995. 117: p. 12299-12305. 
11.  Gilmore, C.J., K. Shankland, and W. Dong, A Maximum Entropy Approach to Structure 
Solution, in Structure Determination from Powder Diffraction Data, W.I.F. David, et al., 
Editors. 2002, Oxford University Press: New York. p. 337. 
12.  Forney, B. Phenylbutazone for Veterinary Use.  2004  [cited; Available from: 
http://www.wedgewoodpharmacy.com/monographs/phenylbutazone.asp. 
13.  Hosokawa, T., et al., Isostructurality among Five Solvates of Phenylbutazone. Crystal Growth 
& Design, 2004. 4(6): p. 1195-1201. 
14.  Ali, S.L., Phenylbutazone, in Analytical profiles of drug substances, K. Florey, Editor. 1991, 
Academic Press: San Diego, London. p. 483-521. 
15.  Hosokawa, T., et al., Relationships between crystal structures and thermodynamic properties 
of phenylbutazone solvates. Crystengcomm, 2004. 6: p. 243-249. 
16.  Ibrahim, H.G., F. Pisano, and A. Bruno, Polymorphism of phenylbutazone: Properties and 
compressional behavior of crystals. Journal of Pharmaceutical Sciences, 1977. 66(5): p. 669-
673. 
17.  Matsunaga, J., N. Nambu, and T. Nagai, Physicochemical Approach to Biopharmaceutical 
Phenomena .30. Polymorphism of Phenylbutazone. Chemical & Pharmaceutical Bulletin, 
1976. 24(6): p. 1169-1172. 
18.  Mueller, B.W., Polymorphism of Non-Steroidal Anti-Inflammatory Drugs .1. Polymorphism 
and Pseudo-Polymorphism of Phenylbutazone. Pharmaceutica Acta Helvetiae, 1978. 53(12): 
p. 333-340. 
19.  Tuladhar, M.D., Effects of polymorphism and particle size on the dissolution of 
phenylbutazone tablets, PhD Thesis, 1982, University of London: London. 
20.  Matsumoto, T., et al., Effect of Environmental-Temperature on the Polymorphic 
Transformation of Phenylbutazone during Grinding. Chemical & Pharmaceutical Bulletin, 
1988. 36(3): p. 1074-1085. 156 
21.  Matsuda, Y., et al., Polymorphism of phenylbutazone by a spray drying method. J Pharm 
Pharmacol, 1980. 32(8): p. 579-80. 
22.  Al-Meshal, M.A.S. and P. York, Effect of Crystallization Rate on the Polymorphism and 
Dissolution of Spray-Dried Phenylbutazone. Journal of Pharmacy and Pharmacology, 1983. 35 
II. 
23.  Matsuda, Y., et al., Physicochemical characterization of spray-dried phenylbutazone 
polymorphs. J Pharm Sci, 1982. 73(2): p. 173-9. 
24.  Matsuda, Y., et al., Kinetic Study of the Polymorphic Transformations of Phenylbutazone. 
Journal of Pharmaceutical Sciences, 1984. 73(10): p. 1453-1461. 
25.  Burger, A. and R. Ramberger, On the Polymorphism of Pharmaceuticals and Other Molecular 
Crystals. II. Mikrochimica Acta, 1979(2): p. 273-316. 
26.  Kaneniwa, N., J. Ichikawa, and K. Hayashi, Dissolution Behavior of Phenylbutazone 
Polymorphs. Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan, 1987. 107(12): 
p. 1005-1007. 
27.  Kaneniwa, N., J. Ichikawa, and T. Matsumoto, Preparation of Phenylbutazone Polymorphs 
and Their Transformation in Solution. Chemical & Pharmaceutical Bulletin, 1988. 36(3): p. 
1063-1073. 
28.  Tuladhar, M.D., J.E. Carless, and M.P. Summers, Thermal behaviour and dissolution 
properties of phenylbutazone polymorphs. J Pharm Pharmacol, 1983. 35(4): p. 208-14. 
29.  Rey-Mermet, C., et al., Significance of Partial and Total Cohesion Parameters of 
Pharmaceutical Solids Determined from Dissolution Calorimetric Measurements. 
Pharmaceutical Research, 1991. 8(5): p. 636-642. 
30.  Hildebrand, J.H., J.M. Prausnitz, and R.L. Scott, Regular & Related Solutions, The Solubility of 
Gases, Liquids and Solids. 1970, New York: Van Nostrand Reinhold. 228. 
31.  Hildebrand, J.H. and R.L. Scott, The solubility of nonelectrolytes. 3rd ed ed. Monograph series 
/ American Chemical Society ; no.17. 1951: Reinhold; Chapman & Hall. 488p., ill.,24cm. 
32.  Hancock, B.C., P. York, and R.C. Rowe, The use of solubility parameters in pharmaceutical 
dosage form design. International Journal of Pharmaceutics, 1997. 148(1): p. 1-21. 
33.  Streng, W.H., Characterization of compounds in solution : theory and practice. 2001, New 
York ; London: Kluwer Academic/Plenum Publishers. xv, 273 p. 
34.  Tuladhar, M.D., J.E. Carless, and M.P. Summers, The effects of polymorphism, particle size 
and compression pressure on the dissolution rate of phenylbutazone tablets. J Pharm 
Pharmacol, 1983. 35(5): p. 269-74. 
35.  Al-Meshal, M.A.S., Physicochemical and tableting properties of crystallised and spray-dried 
phenylbutazone containing polymeric additives. 1985, University of Bradford. 
36.  Stella, V.J., Nonclassical Phase Transfer Behavior of Phenylbutazone. Journal of 
Pharmaceutical Sciences, 1975. 64(4): p. 706-708. 
37.  Stella, V.J. and J.D. Pipkin, Phenylbutazone Ionization Kinetics. Journal of Pharmaceutical 
Sciences, 1976. 65(8): p. 1161-1165. 
38.  Singh, T.P. and M. Vijayan, Structural Studies of Analgesics and Their Interactions .4. Crystal-
Structures of Phenylbutazone and a 2-1 Complex between Phenylbutazone and Piperazine. 
Journal of the Chemical Society-Perkin Transactions 2, 1977(5): p. 693-699. 
39.  Paradies, H.H., Structure of Phenylbutazone and Mofebutazone in the Crystalline State and in 
Solution. Journal of Pharmaceutical Sciences, 1987. 76(12): p. 920-929. 
40.  Chauvet, A. and J. Masse, Du Comportement Thermique de la Phenylbutazone. Travaux de la 
Société de Pharmacie de Montpellier, 1978. 38(1): p. 31-42. 
41.  Borka, L. and J.K. Haleblian, Crystal Polymorphism of Pharmaceuticals. Acta Pharmaceutica 
Jugoslavica, 1990. 40(1-2): p. 71-94. 
42.  Giron, D., Thermal Analysis in Pharmaceutical Routine Analysis. Acta Pharmaceutica 
Jugoslavica, 1990. 40: p. 95-157. 157 
43.  Giron, D., Applications of thermal analysis and coupled techniques in pharmaceutical 
industry. Journal of Thermal Analysis and Calorimetry, 2002. 68(2): p. 335-357. 
44.  Giron, D., Investigations of Polymorphism and Pseudo-Polymorphism in Pharmaceuticals by 
Combined Thermoanalytical Techniques. Journal of Thermal Analysis & Calorimetry, 2001. 
64: p. 37-60. 
45.  Giron, D., Thermal analysis and calorimetric methods in the characterisation of polymorphs 
and solvates. Thermochimica Acta, 1995. 248: p. 1-59. 
46.  Diamond. I11 Powder Diffraction.  2009  [cited; Available from: 
http://www.diamond.ac.uk/Beamlines/Beamlineplan/I11/Index.htm. 
47.  Gottlieb, H.E., V. Kotlyar, and A. Nudelman, NMR Chemical Shifts of Common Laboratory 
Solvents as Trace Impurities. J. Org. Chem., 1997. 62(21): p. 7512-7515. 
48.  Tanaka, M., et al., Binding Position of Phenylbutazone with Bovine Serum Albumin 
Determined by Measuring Nuclear Magnetic Resonance Relaxation Time. Chemical & 
Pharmaceutical Bulletin, 1989. 37(12): p. 3177-3180. 
49.  Simpson, J., Organic Structure Determination Using 2D NMR Spectroscopy. 2009, Oxford: 
Academic Press. 
50.  Ladd, M. and R. Palmer, Structure Determination by X-ray Crystallography. 4 ed. 2003, New 
York: Kluwer Academic/Plenum Publishers. 819. 
51.  Pecharsky, V.K. and P.Y. Zavalij, Fundamentals of Powder Diffraction and Structural 
Characterization of Materials. 1 ed. 2005, New York: Springer. 713. 
52.  Dinnebier, R.E. and S.J.L. Billinge, Powder Diffraction. Theory and Practice. 1 ed. 2008, 
Cambridge: Royal Society of Chemistry. 582. 
53.  Werner, P., Autoindexing, in Structure Determination from Powder Diffraction Data, W.I.F. 
David, et al., Editors. 2002, Oxford University Press: New York. p. 337. 
54.  Powder and Small Molecule Single Crystal Diffraction. Collaboratve Computer Projects 14  
1994  [cited; Available from: www.ccp14.ac.uk. 
55.  Kohlbeck, F. and E.M. Hoerl, Indexing program for powder patterns especially suitable for 
triclinic, monoclinic and orthorhombic lattices. Journal of Applied Crystallography, 1976. 9: p. 
28-33. 
56.  Kohlbeck, F. and E.M. Hoerl, Trial and error indexing program for powder patterns of 
monoclinic substances. Journal of Applied Crystallography, 1978. 11: p. 60-61. 
57.  Datta, S. and D.J.W. Grant, Crystal structures of drugs: Advances in determination, prediction 
and engineering. Nature Reviews Drug Discovery, 2004. 3(1): p. 42-57. 
58.  Cockcroft, J.K., Dragon, Version 5.01. 2003: London. 
59.  Altomare, A., et al., Expo User's Manual, in SIRWARE, I.d. Cristallografia, Editor: Bari. p. A 
package for full pattern decomposition and for solving crystal structures by direct methods. 
60.  IUCr, Space Group Symmetry. International Tables for Crystallography, ed. T. Hahn. Vol. A. 
1995, Dordrecht: Kluwer. 
61.  Massa, W. and R.O. Gould, Crystal structure determination. 2nd ed. 2004, Berlin: Springer. 
xi,210p. 
62.  Young, R.A., Rietveld method. New ed. International Union of Crystallography Monographs 
on Crystallography. 1995, Oxford: Oxford University Press. [308]p. 
63.  Giacovazzo, C., Direct Phasing in Crystallography. 1 ed. IUCr Monographs on Crystallography, 
ed. P. Coppens. 1998, New York: Oxford University Press. 767. 
64.  Bruno, I.J., et al., New software for searching the Cambridge Structural Database and 
visualising crystal structures. Acta Crystallographica Section B, 2002. 58: p. 389-397. 
65.  Kraus, W. and G. Nolze, Powdercell, Bundesanstalt fuer Materialforschung und Pruefung: 
Berlin. p. powder pattern calculation from single crystal data and refinement of 
experimental curves. 158 
66.  Giacovazzo, C., et al., Direct methods in powder diffraction - applications, in Structure 
Determination from Powder Diffraction Data, W.I.F. David, et al., Editors. 2002, Oxford 
University Press: New York. p. 337. 
67.  Favre-Nicolin, V. and R. Cerny, FOX, Free Objects for Xtallography. p. "a free, open-source 
program for the ab initio structure determination from powder diffraction data". 
68.  Palatinus, L. and G. Chapuis, SUPERFLIP - a computer program for the solution of crystal 
structures by charge flipping in arbitrary dimensions. Journal of Applied Crystallography, 
2007. 40: p. 786-790. 
69.  Clegg, W., Crystal Structure Analysis. Texts on Crystallography, ed. IUCr. 2001, Oxford: 
Oxford University Press. 
70.  Keats, C.J., Crystallization and Polymorphism of Putative Drugs, PhD Thesis, 2001, Oxford 
University: Oxford. 
71.  Cockcroft, J.K., Extinguishing of Single Crystals under Polarized Light, J.J. Targett, Editor. 
2007: London. 
72.  Burla, M.C., et al., SIR2004: an improved tool for crystal structure determination and 
refinement. Journal of Applied Crystallography, 2005. 38(381-388). 
73.  Petricek, V., M. Dusek, and L. Palatinus, Jana2006. The crystallographic computing system. 
2006, Institute of Physics: Prague. 
74.  Shmueli, U., Theories & Techniques of Crystal Structure Determination. 1 ed. IUCr Texts on 
Crystallography, ed. H. Schenk. 2007, New York: Oxford University Press. 269. 
75.  Wilson, A.J.C. and E. Prince, International Tables for Crystallography. Vol. C. 1999, Dordrecht, 
London: Published for the International Union of Crystallography by Kluwer Academic 
Publishers. 992p. 
76.  Betteridge, P.W., et al., CRYSTALS, version 12: software for guided crystal structure analysis. 
Journal of Applied Crystallography, 2003. 36. 
77.  Trueblood, K.N., et al., Atomic Dispacement Parameter Nomenclature. Report of a 
Subcommittee on Atomic Displacement Parameter Nomenclature. Acta Crystallographica 
Section A, 1996. 52(5): p. 770-781. 
78.  Mueller, P., Crystal structure refinement : a crystallographers guide to SHELXL. IUCr texts on 
crystallography. 2006, Oxford: Oxford University Press. xvii, 213 p. 
79.  Mullin, J.W., Crystallization. 3rd ed. 1997, Oxford: Butterworth-Heinemann. 
80.  Kitamura, M., Polymorphism in the Crystallization of L-Glutamic Acid. Journal of Crystal 
Growth, 1989. 96(3): p. 541-546. 
81.  Kitamura, M., Crystallization Behaviour and Transformation Kinetics of l-Histidine 
Polymorphs. Journal of Chemical Engineering of Japan, 1993. 26(3): p. 303-307. 
82.  Kitamura, M., Controlling factors and mechanism of polymorphic crystallization. Crystal 
Growth & Design, 2004. 4(6): p. 1153-1159. 
83.  Kitamura, M. and K. Nakamura, Effects of solvent composition and temperature on 
polymorphism and crystallization behavior of thiazole-derivative. Journal of Crystal Growth, 
2002. 236(4): p. 676-686. 
84.  Kitamura, M. and K. Onuma, In situ observation of growth process of alpha-L-glutamic acid 
with atomic force microscopy. Journal of Colloid and Interface Science, 2000. 224(2): p. 311-
316. 
85.  Jacques, S.D.M., et al., An In-Situ Synchrotron X-ray Diffraction Tomography Study of 
Crystallization and Preferred Crystal Orientation in a Stirred Reactor. Crystal Growth & 
Design, 2005. 5(2): p. 395-397. 
86.  Grant, D.J.W. and T. Higuchi, Solubility Behaviour of Organic Compounds. Techniques of 
Chemistry, ed. A. Weissberger and W.J. Saunders. 1990, New York: Wiley. 600. 
87.  Shinoda, K., Principles of solution and solubility. Undergraduate chemistry ; v. 5. 1978, New 
York: M. Dekker. x, 222 p. 159 
88.  Barton, A.F.M., CRC handbook of solubility parameters and other cohesion parameters. 1983, 
Boca Raton, Fla.: CRC Press. [vii],594p. 
89.  Reuteler-Faoro, D., et al., A New Equation for Calculating Partial Cohesion Parameters of 
Solid Substances from Solubilities. Journal of Physical Chemistry, 1988. 92(21): p. 6144-6148. 
90.  Carstensen, J.T., Advanced Pharmaceutical Solids. Drugs and the Pharmaceutical Sciences. 
2001, New York: Marcel Dekker. 
91.  Pudipeddi, M. and A.T.M. Serajuddin, Trends in solubility of polymorphs. Journal of 
Pharmaceutical Sciences, 2005. 94(5): p. 929-939. 
92.  Datta, S. and D.J.W. Grant, Computing the relative nucleation rate of phenylbutazone and 
sulfamerazine in various solvents. Crystal Growth & Design, 2005. 5(4): p. 1351-1357. 
93.  Lewis, T.C., et al., A computational and experimental search for polymorphs of parabanic 
acid - a salutary tale leading to the crystal structure of oxo-ureido-acetic acid methyl ester. 
Crystengcomm, 2003: p. 3-9. 
94.  Gu, C.H., V. Young, and D.J.W. Grant, Polymorph screening: Influence of solvents on the rate 
of solvent-mediated polymorphic transformation. Journal of Pharmaceutical Sciences, 2001. 
90(11): p. 1878-1890. 
95.  Blagden, N. and R.J. Davey, Polymorph Selection: Challenges for the Future? Crystal Growth 
& Design, 2003. 3(6): p. 873-885. 
96.  Threlfall, T., Crystallisation of Polymorphs: Thermodynamic Insight into the Role of Solvent. 
Organic Process Research & Development, 2000(4): p. 384-390. 
97.  Bernstein, J., R.J. Davey, and J.O. Henck, Concomitant polymorphs. Angewandte Chemie-
International Edition, 1999. 38(23): p. 3441-3461. 
98.  Datta, S. and D.J.W. Grant, Effect of supersaturation on the crystallization of phenylbutazone 
polymorphs. Crystal Research and Technology, 2005. 40(3): p. 233-242. 
99.  Aguiar, A.J., et al., Effect of polymorphism on the absorption of chloramphenicol from 
chloramphenicol palmitate. J Pharm Sci, 1967. 56(7): p. 847-53. 
100.  Burger, A. and R. Ramberger, On the Polymorphism of Pharmaceuticals and Other Molecular 
Crystals. I. Mikrochimica Acta, 1979(2): p. 259-271. 
101.  Gu, C.H. and D.J.W. Grant, Estimating the relative stability of polymorphs and hydrates from 
heats of solution and solubility data. Journal of Pharmaceutical Sciences, 2001. 90(9): p. 
1277-1287. 
102.  Urakami, K., et al., A novel method for estimation of transition temperature for polymorphic 
pairs in pharmaceuticals using heat of solution and solubility data. Chemical & 
Pharmaceutical Bulletin, 2002. 50(2): p. 263-267. 
103.  Brown, M.E., Reaction Kinetics from Thermal Analysis, in Introduction to Thermal Analysis. 
2001, Kluwer: Dordrecht. p. 181-214. 
104.  Jenkins, R., R.W. Gould, and D. Gedcke, Quantitative X-ray spectrometry. 2nd ed. Practical 
spectroscopy series ; vol. 20. 1995, New York, N.Y.: Dekker. xi,484p. 
105.  Klug, H.P., L. Alexander, and E. Kummer, Quantitative Analysis with the X-Ray Spectrometer - 
Accuracy and Reproducibility. Analytical Chemistry, 1948. 20(7): p. 607-609. 
106.  Zevin, L.S., G. Kimmel, and I. Mureinik, Quantitative X-ray Diffractometry. 1995, New York ; 
London: Springer. xvii, 372 p. 
107.  Wong, E.R., et al., Scrip - Fortran-IV Software for Quantitative XRD. Advances in X-Ray 
Analysis, 1983. 26: p. 157-162. 
108.  Walton, R.I., et al., An in situ energy-dispersive X-ray diffraction study of the hydrothermal 
crystallization of zeolite A. 1. Influence of reaction conditions and transformation into 
sodalite. Journal of Physical Chemistry B, 2001. 105(1): p. 83-90. 
109.  Turrillas, X., et al., Synchrotron-related studies on the dynamic and structural aspects of 
zirconia synthesis for ceramic and catalytic applications. Radiation Physics and Chemistry, 
1995. 45(3): p. 491-508. 160 
110.  Khawam, A. and D.R. Flanagan, Basics and applications of solid-state kinetics: A 
pharmaceutical perspective. Journal of pharmaceutical sciences, 2006. 95(3): p. 472-498. 
111.  Criado, J.M., A. Ortega, and F. Gotor, Correlation between the shape of controlled-rate 
thermal analysis curves and the kinetics of solid-state reactions. Thermochimica Acta, 1990. 
157(1): p. 171-179. 
112.  Brown, M.E., ed. Handbook of Thermal Analysis and Calorimetry. ed. P.K. Gallagher. Vol. 1. 
1998, Elsevier: Amsterdam. 
113.  Galwey, A.K. and M.E. Brown, Thermal decomposition of ionic solids. Studies in physical and 
theoretical chemistry. 1999, Amsterdam ; New York: Elsevier. xxvi, 597 p. 
114.  Freeman, E.S. and B. Carroll, The Application of Thermoanalytical Techniques to Reaction 
Kinetics: The Thermogravimetric Evaluation of the Kinetics of the Decomposition of Calcium 
Oxalate Monohydrate. The Journal of Physical Chemistry, 1958. 62(4): p. 394-397. 
115.  Freeman, E.S. and B. Carroll, Interpretation of the kinetics of thermogravimetric analysis. The 
Journal of Physical Chemistry, 1969. 73(3): p. 751-752. 
116.  Forni, F., et al., Thermal behaviour of melt crystallized phenylbutazone. Journal of Thermal 
Analysis and Calorimetry, 1990. 36(1): p. 35-44. 
117.  Beretzky, A., et al., Pelletization of needle-shaped phenylbutazone crystals. Journal of 
Thermal Analysis and Calorimetry, 2002. 69(2): p. 529-539. 
118.  Gedcke, D. (2005) How Counting Statistics Controls Detection Limits and Peak Precision. 
Application Note, Ortec Incorporated Volume, 8  
 161 
 
Appendix 1 – Reference PXRD Patterns of Phenylbutazone’s Polymorphs 
 
Alpha Form (Synchrotron Data) 
 162 
Index Positions of Phenylbutazone Alpha in P2(1)/c 
(a = 21.415Å, b = 5.729Å, c = 27.782Å, alpha = gamma = 90°, beta = 108.068°) (CuKα radiation)  
H K L D 2-theta H K L D 2-theta H K L D 2-theta
1 0 0 20.359 4.337 -2 1 3 4.658 19.039 4 1 0 3.805 23.3591
0 0 2 13.206 6.688 -1 0 6 4.608 19.2461 -3 1 5 3.7605 23.6398
-1 0 2 13.086 6.749 -2 0 6 4.593 19.3112 2 1 4 3.7195 23.9041
2 0 0 10.180 8.679 1 1 3 4.506 19.6838 -4 1 4 3.6873 24.1157
1 0 2 9.781 9.034 -3 1 1 4.465 19.867 1 1 5 3.6641 24.2711
-2 0 2 9.636 9.170 2 1 2 4.451 19.9294 2 0 6 3.6491 24.3723
2 0 2 7.071 12.507 -3 1 2 4.428 20.0344 4 1 1 3.6486 24.3754
-3 0 2 6.980 12.672 -1 1 4 4.419 20.0756 3 1 3 3.6402 24.4326
-1 0 4 6.945 12.736 0 0 6 4.402 20.1554 -5 0 6 3.5964 24.7349
3 0 0 6.786 13.035 3 1 0 4.378 20.2687 -1 1 6 3.5906 24.7755
0 0 4 6.603 13.398 -3 0 6 4.362 20.342 5 0 2 3.5901 24.7787
-2 0 4 6.543 13.522 0 1 4 4.327 20.5073 -2 1 6 3.5833 24.8268
1 0 4 5.777 15.325 4 0 2 4.321 20.5384 -6 0 2 3.5636 24.9663
-3 0 4 5.697 15.540 -2 1 4 4.310 20.589 4 0 4 3.5357 25.1668
0 1 1 5.599 15.816 -5 0 2 4.283 20.7216 -2 0 8 3.4724 25.6333
1 1 0 5.515 16.058 -3 1 3 4.276 20.7575 -3 1 6 3.4706 25.6468
-1 1 1 5.492 16.127 3 1 1 4.186 21.2084 4 1 2 3.4497 25.8048
3 0 2 5.394 16.420 3 0 4 4.135 21.4731 -1 0 8 3.4314 25.9444
-4 0 2 5.337 16.597 2 1 3 4.085 21.7406 -5 1 2 3.4303 25.9527
1 1 1 5.310 16.682 -5 0 4 4.076 21.7845 -3 0 8 3.4145 26.0752
0 1 2 5.256 16.855 5 0 0 4.072 21.8092 -5 1 3 3.4024 26.1693
-1 1 2 5.248 16.880 1 1 4 4.068 21.8303 -5 1 1 3.4011 26.1797
4 0 0 5.090 17.409 1 0 6 4.051 21.9232 6 0 0 3.3932 26.2421
-2 1 1 5.048 17.555 -3 1 4 4.040 21.9841 2 1 5 3.3808 26.3399
2 1 0 4.993 17.751 -4 0 6 3.999 22.2096 3 1 4 3.3528 26.5641
1 1 2 4.943 17.929 -1 1 5 3.986 22.2864 -5 1 4 3.3214 26.8196
-2 1 2 4.924 17.999 -2 1 5 3.940 22.5485 5 1 0 3.3189 26.84
2 0 4 4.890 18.125 3 1 2 3.927 22.6223 1 1 6 3.3076 26.9339
-1 1 3 4.861 18.235 -4 1 2 3.905 22.7525 0 0 8 3.3015 26.9843
-4 0 4 4.818 18.400 -4 1 1 3.896 22.8075 -4 1 6 3.2793 27.1704  163 
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Appendix 1 – Reference PXRD Patterns of Phenylbutazone’s Polymorphs 
Delta Form (Synchrotron Data) 165 
Index Positions of Phenylbutazone Delta in Pnnm (or Pnn2) 
(a = 34.147Å, b = 34.816Å, c = 5.7506Å, alpha = beta = gamma = 90) (CuKα radiation)  
H K L D 2-theta H K L D 2-theta H K L D 2-theta
1 1 0 24.379 3.621 6 1 0 5.617 15.765 0 5 1 4.434 20.008
0 2 0 17.408 5.072 1 1 1 5.597 15.821 5 6 0 4.422 20.063
2 0 0 17.073 5.172 2 6 0 5.494 16.119 3 4 1 4.421 20.067
1 2 0 15.509 5.694 6 2 0 5.409 16.373 4 3 1 4.411 20.112
2 1 0 15.329 5.761 4 5 0 5.396 16.415 6 5 0 4.407 20.134
2 2 0 12.189 7.246 1 2 1 5.392 16.427 5 0 1 4.399 20.170
1 3 0 10.988 8.040 2 1 1 5.384 16.450 1 5 1 4.397 20.178
3 1 0 10.819 8.166 5 4 0 5.373 16.485 5 1 1 4.364 20.332
2 3 0 9.598 9.206 2 2 1 5.201 17.034 0 8 0 4.352 20.389
3 2 0 9.527 9.276 3 6 0 5.170 17.138 1 8 0 4.317 20.556
0 4 0 8.704 10.154 0 3 1 5.153 17.195 4 7 0 4.298 20.651
4 0 0 8.537 10.354 3 0 1 5.133 17.262 2 5 1 4.292 20.679
1 4 0 8.434 10.480 6 3 0 5.110 17.340 8 0 0 4.268 20.794
4 1 0 8.291 10.662 1 3 1 5.095 17.391 5 2 1 4.265 20.811
3 3 0 8.126 10.878 3 1 1 5.078 17.450 7 4 0 4.255 20.858
2 4 0 7.755 11.402 2 3 1 4.933 17.967 8 1 0 4.237 20.951
4 2 0 7.665 11.536 3 2 1 4.923 18.003 2 8 0 4.217 21.049
3 4 0 6.914 12.793 1 7 0 4.922 18.008 4 4 1 4.183 21.225
4 3 0 6.877 12.863 5 5 0 4.876 18.180 8 2 0 4.146 21.417
1 5 0 6.823 12.965 7 1 0 4.831 18.350 3 5 1 4.132 21.490
5 1 0 6.702 13.200 4 6 0 4.799 18.473 5 3 1 4.113 21.587
2 5 0 6.448 13.723 2 7 0 4.775 18.565 3 8 0 4.065 21.846
5 2 0 6.358 13.918 6 4 0 4.763 18.613 6 6 0 4.063 21.856
4 4 0 6.095 14.522 1 4 1 4.751 18.660 1 6 1 4.056 21.897
3 5 0 5.940 14.902 4 1 1 4.725 18.764 5 7 0 4.021 22.091
5 3 0 5.886 15.040 7 2 0 4.697 18.877 6 1 1 4.018 22.105
0 6 0 5.803 15.256 3 3 1 4.694 18.889 8 3 0 4.006 22.172
1 6 0 5.721 15.477 2 4 1 4.619 19.199 7 5 0 3.995 22.232
6 0 0 5.691 15.558 4 2 1 4.600 19.280 2 6 1 3.973 22.361
0 1 1 5.674 15.605 3 7 0 4.558 19.460 6 2 1 3.940 22.548
1 0 1 5.671 15.614 7 3 0 4.497 19.725 4 5 1 3.935 22.578 166 
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Appendix 4 – 
1H NMR Spectrum of Phenylbutazone in CDCl3 
 
Group Number 
Predicted Chemical Shift by 
Group (ppm) 
Observed Chemical Shift 
by Group (ppm) 
Peak Magnitude 
(Tanaka et al. & Yang et al.)  (Tanaka et al.)    T = Trace, W = weak 
M = Medium, S = Strong 
    0.61286  T 
    0.77865  T 
1  0.900  0.8909  S 
CH3    0.90545  S 
    92009  S 
2  1.356  1.34957  W 
CH2    1.36424  W 
    1.37906  W 
    1.39371  W 
3  1.479  1.4463  W 
CH2    1.47342  W 
    1.47903  W 
    1.48591  W 
    1.49384  W 
    1.50041  W 
    1.50629  W 
    1.5109  W 
H2O  1.56  1.57882  W 
4  2.084  2.06789  W 
CH2    2.07956  W 
    2.0844  W 
    2.08904  W 
    2.09598  W 
    2.10042  W 
    2.11189  W 
?    2.30353  T 
5  3.384  3.25404  M 
CH    3.37803  M 
    3.38953  M 
    3.40106  M 
    3.42906  M 
    3.44087  M 
    3.50962  M 
    3.52157  M 
    4.2875  T 
    4.31284  T 
    5.2689  T 
    5.62753  T 
    7.02237  T 171 
6  7.170  7.15373  M 
Phenyl    7.16145  M 
para    7.16962  M 
    7.17876  M 
    7.1875  M 
    7.19616  M 
    7.20487  M 
Solvent Residual 
 
7.25  7.2581  S 
7  7.314  7.27994  S 
Phenyl    7.29433  S 
meta    7.30023  S 
ortho    7.30983  S 
    7.31853  S 
    7.33623  S 
    7.34911  S 
    7.3582  S 
    7.47459  T 172 
Appendix 5 – Treatment of Background Counts 
 
The approach recommended by a number of manufacturers of X-ray diffraction equipment, 
and adopted by a number of texts on X-ray diffraction in order to characterise the incidence 
of background counts in X-ray diffraction experiments is to consider the arrival of individual 
X-ray photons at the detector. Gedcke, [118], describes the arrival times at the detector in 
terms of a queuing phenomenon in which the time for an individual photon to be registered 
by the detector is infinitesimally small. These arrivals may therefore be regarded as discrete 
events which, when occurring in large enough numbers at a particular detection step, display 
a good approximation to the Poisson distribution. The applicability of the poisonnian queuing 
approximation is supported by the postulate that individual X-ray photons travel along 
different path lengths en route to the detector, both in PXRD and SCXRD experiments.  
The practicalities of constructing detectors with infinitesimally short counting times and low 
or no dead times between counting events, does not, in the opinion of Jenkins et al., [104], 
jeopardize the integrity of such an approximation. Having established the poissonian nature 
of the counting events, the treatment of errors then follows directly.  










N = Number of events in a finite time interval of duration, t 
μ = Average count number of events in time interval, t 
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In the case of X-ray photons reaching a point detector, the event is a single count at a 
detector. For the Poisson probability distribution, the standard deviation of the occurrence of 
count number, N, is defined as follows: 
  N    
In single crystal diffractometry the quantity above is frequently referred to as the standard 
error in the raw count statistic; this is calculated prior to data reduction. 
Where the measurement time at a particular measurement angle is repeated several times, 
Gedke makes the further approximation that the average number of counts, N, in the 
reference counting period, t, will approach the mean value, μ. He states as an assumption that 
counting events are uniformly and randomly distributed over the sampling intervals. This 
simplification is also made by Massa, [61]. Presumably such an approach may also 
encompass the use of extended count times, which are sufficiently long such that the count 
time may be considered as an aggregate of a number of time intervals, t. 
Treatment of the background is handled simply by many crystallographic software programs 
that include a background subtraction algorithm; for example many of the software programs 
designed to carry out LeBail extractions of intensities. Typically the background is assumed 
to be constant, and a line is drawn under the peak representing the level of the background in 
the region of interest were that region not to contain a diffraction peak. In cases where the 
baseline is non-linear, programs often allow a sloped, linear background line to be applied 
beneath the peak; the user is usually able to set his or her own choice of reference 
background points that delimit the region of interest. This graphical approach allows the 
analyst to cope with the non-linear baselines that are frequently encountered in diffraction 
experiments. For quantitative X-ray analysis, a mathematical approach based upon a gaussian 174 
approximation to the Poisson probability density function is outlined by Gedcke, however it 
is not reproduced here. 
During this investigation an analysis of background counts was performed. PXRD patterns 
were collected on prepared mixtures of the alpha and delta forms using high counting times 
to obtain a large population of background counts for each measurement step of 0.05° 2theta. 
A maximum background count number was estimated, and subsequently used to filter 
background from non-background steps. A histogram of counts per background measurement 
step is shown below.  






























































Count Range of Individual Background Points
20:80 A:D - Mean 198.8, S.D. 81.1
40:60 A:D - Mean 186.2, S.D. 129.9
60:40 A:D - Mean 208.3, S.D. 82.7
80:20 A:D - Mean 218.6, S.D. 85.5
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The distribution displays a count range with a maximum number of 2theta step observations 
followed by a clear drop off thereafter. In these experiments the drop-off is observed to occur 
in the range of 280-320 counts. 
Indexing assumptions enable the crystallographer to build an informed opinion about the 
location of peak information, with which previous background assumptions can be checked 
and modified. Although this iterative process is laborious when compared with the simplicity 
of auto-background subtraction algorithms, it provides a clearer understanding of the baseline 
assumptions, and is likelier to draw attention to errors in indexing or space-group assignment.  
 176 
List of Abbreviations 
 
Below is a listing of abbreviations used in the text: 
API      Active Pharmaceutical Ingredient 
CIF      Crystallographic Information File 
CSD      Cambridge Structural Database 
DSC      Differential Scanning Calorimetry 
FOM      Figure of Merit 
IR      InfraRed (Spectrometry) 
IUCr      International Union of Crystallography 
NMR      Nuclear Magnetic Resonance 
PDF      Powder Diffraction File, or 
      Probability Density Function 
 
PPM      Parts per Million 
PXRD     Powder X-ray Diffraction 
SCXRD    Single Crystal X-ray Diffraction 
SD      Standard Deviation 
TGA      Thermogravimetric Analysis 